DSS (DSS) 10-Q 14 Nov 22 2022 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2022	Nov. 09, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2022
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	001-32146
Entity Registrant Name	DSS, INC.
Entity Central Index Key	0000771999
Entity Tax Identification Number	16-1229730
Entity Incorporation, State or Country Code	NY
Entity Address, Address Line One	275 Wiregrass Pkwy
Entity Address, City or Town	West Henrietta
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	14586
City Area Code	(585)
Local Phone Number	325-3610
Title of 12(b) Security	Common Stock, $0.02 par value per share
Trading Symbol	DSS
Security Exchange Name	NYSE
Entity Current Reporting Status	No
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		139,017,172

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 22,845,000	$ 56,595,000
Accounts receivable, net	8,989,000	5,673,000
Inventory	8,663,000	8,261,000
Current portion of notes receivable	12,273,000	6,310,000
Prepaid expenses and other current assets	2,898,000	3,466,000
Total current assets	55,668,000	80,305,000
Property, plant and equipment, net	16,065,000	17,674,000
Investment in real estate, net	55,493,000	56,374,000
Other investments	8,190,000	11,001,000
Investment, equity method	1,326,000	1,080,000
Marketable securities	28,083,000	14,172,000
Notes receivable	1,704,000	5,878,000
Other assets	1,393,000	489,000
Right-of-use assets	8,459,000	498,000
Goodwill	56,606,000	56,606,000
Other intangible assets, net	31,893,000	38,630,000
Total assets	264,880,000	282,707,000
Current liabilities:
Accounts payable	4,048,000	1,920,000
Accrued expenses and deferred revenue	11,627,000	21,180,000
Other current liabilities	396,000	402,000
Current portion of lease liability	819,000	393,000
Current portion of long-term debt, net	6,680,000	3,916,000
Total current liabilities	23,570,000	27,811,000
Long-term debt, net	50,163,000	55,711,000
Long term lease liability	7,991,000	120,000
Other long-term liabilities	507,000	880,000
Commitments and contingencies (Note 9)
Stockholders’ equity
Preferred stock, $.02 par value; 47,000 shares authorized, zero shares issued and outstanding (zero on December 31, 2021); Liquidation value $1,000 per share, zero aggregate. zero on December 31, 2021).
Common stock, $.02 par value; 200,000,000 shares authorized, 139,017,172 shares issued and outstanding (79,745,886 on December 31, 2021)	2,779,000	1,594,000
Additional paid-in capital	317,125,000	294,685,000
Accumulated deficit	(167,417,000)	(134,503,000)
Total stockholders’ equity	152,487,000	161,776,000
Non-controlling interest in subsidiaries	30,162,000	36,409,000
Total stockholders’ equity	182,649,000	198,185,000
Total liabilities and stockholders’ equity	$ 264,880,000	$ 282,707,000

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)	Sep. 30, 2022	Jun. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.02		$ 0.02
Preferred stock, shares authorized	47,000		47,000
Preferred stock, shares issued	0		0
Preferred stock, shares outstanding		0	0
Preferred stock, liquidation preference per share	$ 1,000		$ 1,000
Preferred stock, liquidation preference	$ 0		$ 0
Common stock, par value	$ 0.02		$ 0.02
Common stock, shares authorized	200,000,000		200,000,000
Common stock, shares issued	139,017,172		79,745,886
Common stock, shares outstanding	139,017,172		79,745,886

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenue:
Total revenue	$ 11,862,000	$ 4,566,000	$ 35,927,000	$ 13,218,000
Costs and expenses:
Cost of revenue	11,368,000	3,406,000	27,653,000	10,045,000
Selling, general and administrative (including stock based compensation)	14,677,000	6,705,000	40,316,000	19,164,000
Total costs and expenses	26,045,000	10,111,000	67,969,000	29,209,000
Operating loss	(14,183,000)	(5,545,000)	(32,042,000)	(15,991,000)
Other income (expense):
Interest income	319,000	1,593,000	613,000	3,130,000
Other income (expense)	3,627,000	325,000	4,203,000	575,000
Interest expense	(606,000)	(31,000)	(2,105,000)	(157,000)
Gain on extinguishment of debt			110,000	116,000
Gain/(loss) on equity method investment	344,000	(1,645,000)	134,000	(2,556,000)
Loss on investments	(14,302,000)	(2,996,000)	(10,479,000)	(10,894,000)
Gain on sale of assets			405,000
Loss from continuing operations before income taxes	(24,801,000)	(8,299,000)	(39,161,000)	(25,777,000)
Income tax benefit		1,624,000		4,315,000
Loss from continuing operations	(24,801,000)	(6,675,000)	(39,161,000)	(21,462,000)
Income from discontinued operations, net of tax				2,129,000
Net loss	(24,801,000)	(6,675,000)	(39,161,000)	(19,333,000)
Loss from continuing operations attributed to noncontrolling interest	4,587,000	77,000	6,247,000	336,000
Net loss attributable to common stockholders	$ (20,214,000)	$ (6,598,000)	$ (32,914,000)	$ (18,997,000)
Loss per common share:
Basic	$ (0.15)	$ (0.19)	$ (0.32)	$ (0.78)
Diluted	(0.15)	(0.19)	(0.32)	(0.78)
Earnings per common share - discontinued operations:
Basic				0.08
Diluted				$ 0.08
Shares used in computing loss per common share:
Basic	134,893,360	34,888,054	102,390,079	27,203,137
Diluted	134,893,360	34,888,054	102,390,079	27,203,137
Printed Products [Member]
Revenue:
Total revenue	$ 5,032,000	$ 3,416,000	$ 12,650,000	$ 10,652,000
Rental Income [Member]
Revenue:
Total revenue	1,485,000	184,000	4,656,000	184,000
Management Fee Income [Member]
Revenue:
Total revenue	38,000		38,000
Net Investment Income [Member]
Revenue:
Total revenue	370,000		644,000
Direct Marketing [Member]
Revenue:
Total revenue	$ 4,937,000	$ 966,000	$ 17,939,000	$ 2,382,000

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities:
Net loss from continuing operations	$ (39,161,000)	$ (21,462,000)
Adjustments to reconcile net loss from continuing operations to net cash used by operating activities:
Depreciation and amortization	9,351,000	2,075,000
Stock based compensation	4,000	74,000
Gain/(loss) on equity method investment	(134,000)	2,556,000
Loss (gain) on investments	10,479,000	10,894,000
Loss on allowance for obsolescence of inventory	326,000
Change in ROU assets and lease liabilities, net	336,000
Gain on extinguishment of debt	(110,000)	(116,000)
Deferred tax benefit		(4,315,000)
Accretion of debt discount, origination fee and prepaid interest		(2,287,000)
Gain on sale of assets	(405,000)
Impairment of notes receivable and other investments	1,899,000
Decrease (increase) in assets:
Accounts receivable	(3,316,000)	829,000
Inventory	(728,000)	(1,580,000)
Prepaid expenses and other current assets	568,000	(277,000)
Other assets	(904,000)	(25,000)
Increase (decrease) in liabilities:
Accounts payable	2,128,000	432,000
Accrued expenses	(3,205,000)	1,808,000
Other liabilities	(379,000)	(1,054,000)
Net cash used by operating activities	(23,251,000)	(12,448,000)
Cash flows from investing activities:
Purchase of property, plant and equipment	(1,349,000)	(2,816,000)
Purchase of real estate	(689,000)	(6,565,000)
Purchase of investment		(19,026,000)
Purchase of marketable securities	(14,254,000)	(8,789,000)
Disposal of property, plant and equipment	2,557,000
Asset acquired with APB acquisition		1,235,000
Purchase of equity investment		(1,276,000)
Sale of marketable securities		9,185,000
Issuance of new notes receivable, net origination fees	(4,687,000)	(24,048,000)
Payments received on notes receivable	786,000
Purchase of intangible assets	(180,000)	(1,115,000)
Net cash used by investing activities	(17,816,000)	(53,215,000)
Cash flows from financing activities:
Payments of long-term debt	(561,000)	(1,893,000)
Borrowings of long-term debt	6,360,000	7,102,000
Deferred financing fees		(186,000)
Issuances of common stock, net of issuance costs	1,518,000	121,737,000
Net cash provided by financing activities	7,317,000	126,760,000
Cash flows from discontinued operations:
Cash provided by discontinued operations		207,000
Cash provided by investing activities		3,000,000
Net cash used by discontinued operations		3,207,000
Net increase (decrease) in cash	(33,750,000)	64,304,000
Cash and cash equivalents at beginning of period	56,595,000	5,183,000
Cash and cash equivalents at end of period	$ 22,845,000	$ 69,487,000

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Preferred Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Parent [Member]	Noncontrolling Interest [Member]	Total
Beginning balance at Dec. 31, 2020	$ 116,000	$ 1,000	$ 174,380,000	$ (101,382,000)	$ 73,115,000	$ 3,430,000	$ 76,545,000
Beginning balance, shares at Dec. 31, 2020	5,836,000	43,000
Issuance of common stock, net of expenses	$ 1,347,000		120,434,000		121,781,000		121,781,000
Issuance of common stock, net of expenses, shares	67,340,000
Stock based payments			(2,000)		(2,000)		(2,000)
Net loss				(18,997,000)	(18,997,000)	(336,000)	(19,333,000)
Conversion of preferred stock	$ 131,000	$ (1,000)	(130,000)
Conversion of preferred stock, shares	6,570,000	(43,000)
Acquisition of American Pacific Bancorp						20,301,000	20,301,000
Ending balance at Sep. 30, 2021	$ 1,594,000		294,682,000	(120,379,000)	175,897,000	23,395,000	199,292,000
Ending balance, shares at Sep. 30, 2021	79,746,000
Beginning balance at Dec. 31, 2021	$ 1,594,000		294,685,000	(134,503,000)	161,776,000	36,409,000	198,185,000
Beginning balance, shares at Dec. 31, 2021	79,746,000
Issuance of common stock, net of expenses	$ 858,000		16,547,000		17,405,000		17,405,000
Issuance of common stock, net of expenses, shares	42,924,000
Stock based payments	$ 327,000		5,893,000		6,220,000		6,220,000
Stock based payments, shares	16,347,000
Net loss				(32,914,000)	(32,914,000)	(6,247,000)	(39,161,000)
Ending balance at Sep. 30, 2022	$ 2,779,000		$ 317,125,000	$ (167,417,000)	$ 152,487,000	$ 30,162,000	$ 182,649,000
Ending balance, shares at Sep. 30, 2022	139,017,000

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation and Significant Accounting Policies	1. Basis of Presentation and Significant Accounting Policies The Company, incorporated in the state of New York in May 1984 has conducted business in the name of Document Security Systems, Inc. On September 16, 2021, the board of directors approved an agreement and plan of merger with a wholly owned subsidiary, DSS, Inc. (a New York corporation, incorporated in August 2020), for the sole purpose of effecting a name change from Document Security Systems, Inc. to DSS, Inc. This change became effective on September 30, 2021. DSS, Inc. maintained the same trading symbol “DSS” and updated its CUSIP number to 26253C 102. DSS, Inc. (together with its consolidated subsidiaries, referred to herein as “DSS,” “we,” “us,” “our” or the “Company”) currently operates nine (9) distinct business lines with operations and locations around the globe. These business lines are: (1) Product Packaging, (2) Biotechnology, (3) Direct Marketing, (4) Commercial Lending, (5) Securities and Investment Management, (6) Alternative Trading (7) Digital Transformation, (8) Secure Living, and (9) Alternative Energy. Each of these business lines are in different stages of development, growth, and income generation. Our divisions, their business lines, subsidiaries, and operating territories: (1) Our Product Packaging line is led by Premier Packaging Corporation, Inc. (“Premier”), a New York corporation. Premier operates in the paper board and fiber based folding carton, consumer product packaging, and document security printing markets. It markets, manufactures, and sells sophisticated custom folding cartons, mailers, photo sleeves and complex 3-dimensional direct mail solutions. Premier is currently located in its new facility in Rochester, NY, and primarily serves the US market. (2) The Biotechnology business line was created to invest in or acquire companies in the BioHealth and BioMedical fields, including businesses focused on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune related diseases. This division is also targeting unmet, urgent medical needs, and is developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza. (3) Direct Marketing, led by the holding corporation, Decentralized Sharing Systems, Inc. (“Decentralized”) provides services to assist companies in the emerging growth “Gig” business model of peer-to-peer decentralized sharing marketplaces. Direct specializes in marketing and distributing its products and services through its subsidiary and partner network, using the popular gig economic marketing strategy as a form of direct marketing. Direct Marketing’s products include, among other things, nutritional and personal care products sold throughout North America, Asia Pacific, Middle East, and Eastern Europe. (4) Our Commercial Lending business division, driven by American Pacific Bancorp (“APB”), is organized for the purposes of being a financial network holding company, focused on acquiring equity positions in (i) undervalued commercial bank(s), bank holding companies and nonbanking licensed financial companies operating in the United States, South East Asia, Taiwan, Japan and South Korea, and (ii) companies engaged in—nonbanking activities closely related to banking, including loan syndication services, mortgage banking, trust and escrow services, banking technology, loan servicing, equipment leasing, problem asset management, SPAC (special purpose acquisition company) consulting services, and advisory capital raising services. (5) Securities and Investment Management was established to develop and/or acquire assets in the securities trading or management arena, and to pursue, among other product and service lines, broker dealers, and mutual funds management. Also in this segment is the Company’s real estate investment trusts (“REIT”), organized for the purposes of acquiring hospitals and other acute or post-acute care centers from leading clinical operators with dominant market share in secondary and tertiary markets, and leasing each property to a single operator under a triple-net lease. the REIT was formed to originate, acquire, and lease a credit-centric portfolio of licensed medical real estate. (6) Alternative Trading was established to develop and/or acquire assets and investments in the securities trading and/or funds management arena. Alternative Trading, in partnership with recognized global leaders in alternative trading systems, intends to own and operate in the US a single or multiple vertical digital asset exchanges for securities, tokenized assets, utility tokens, and cryptocurrency via an alternative trading platform using blockchain technology. The scope of services within this section is planned to include asset issuance and allocation (securities and cryptocurrency), FPO, IPO, ITO, PPO, and UTO listings on a primary market(s), asset digitization/tokenization (securities, currency, and cryptocurrency), and the listing and trading of digital assets (securities and cryptocurrency) on a secondary market(s). (7) Digital Transformation was established to be a Preferred Technology Partner and Application Development Solution for mid cap brands in various industries including the direct selling and affiliate marketing sector. Digital improves marketing, communications and operations processes with custom software development and implementation. (8) The Secure Living division has developed a plan for fully sustainable, secure, connected, and healthy living communities with homes incorporating advanced technology, energy efficiency, and quality of life living environments both for new construction and renovations for single and multi-family residential housing. (9) The Alternative Energy group was established to help lead the Company’s future in the clean energy business that focuses on environmentally responsible and sustainable measures. Alset Energy, Inc, the holding company for this group, and its wholly owned subsidiary, Alset Solar, Inc., pursue utility-scale solar farms to serve US regional power grids and to provide underutilized properties with small microgrids for independent energy. On September 9, 2021, the Company finalized a stock purchase agreement (the “SPA”) with American Pacific Bancorp, Inc. (“APB”), which provided for an investment of $ 40,000,200 6,666,700 0.01 6.00 On September 13, 2021, the Company finalized a shareholder agreement between its subsidiary, DSS Financial Management, Inc. (“DFMI”) and HR1 Holdings Limited (“HR1”), a company incorporated in the British Virgin Islands, for the purpose of operating a vehicle for private and institutional investors seeking a highly liquid investment fund with attractive risk adjusted returns relative to market unpredictability and volatility. Under the terms of this agreement, 4000 shares or 40% of the Company’s subsidiary Liquid Asset Limited Management Limited (“LVAM”), a Hong Kong company was transferred to HR1 whereas at the conclusion of the transaction DFMI would own 60% of LVAM and HR1 would own 40%. LVAM executes within reliable platforms and broad market access and uses proprietary systems and algorithms to trade liquid exchange-traded funds (ETFs), stocks, futures or crypto. Aimed at providing consistent returns while offering the unique ability to liquidate the portfolio within 5 to 10 minutes under normal market conditions, LVAM provides an array of advanced tools and products enabling customers to explore multiple opportunities, strengthen and diversify their portfolios, and meet their individual investing goals On December 23, 2021, DSS purchased 50,000,000 0.06 58% The accompanying condensed consolidated financial statements contain all adjustments (consisting of normal recurring adjustments, unless otherwise indicated) necessary to present fairly our consolidated financial position as of September 30, 2022 and December 31, 2021, and the results of our consolidated operations for the interim periods presented. We follow the same accounting policies when preparing quarterly financial data as we use for preparing annual data. These statements should be read in conjunction with the consolidated financial statements and the notes included in our latest annual report on Form 10-K, and 10-K/A for the fiscal year ended December 31, 2021 (“Form 10-K”, “Form 10-K/A”), and our other reports on file with the Securities and Exchange Commission (the “SEC”). Principles of Consolidation Use of Estimates Reclassifications Cash Equivalents Notes receivable, unearned interest, and related recognition Investments For equity method investments, the Company regularly reviews its investments to determine whether there is a decline in fair value below book value. If there is a decline that is other-than-temporary, the investment is written down to fair value. See Note 6 for further discussion on investments. Fair Value of Financial Instruments - ● Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets. ● Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and ● Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. The carrying amounts reported in the consolidated balance sheet of cash and cash equivalents, accounts receivable, prepaids, accounts payable and accrued expenses approximate fair value because of the immediate or short-term maturity of these financial instruments. Marketable securities classify as a Level 1 fair value financial instrument. The fair value of notes receivable approximates their carrying value as the stated or discounted rates of the notes do not reflect recent market conditions. The fair value of revolving credit lines notes payable and long-term debt approximates their carrying value as the stated or discounted rates of the debt reflect recent market conditions. The fair value of investments where the fair value is not considered readily determinable, are carried at cost. Inventory 434,000 388,000 Impairment of Long-Lived Assets and Goodwill Acquisitions Acquisition of assets are recorded at their relative fair value based on total accumulated costs of the acquisition. Direct acquisition-related costs are capitalized as a component of the acquired assets. This includes all costs related to finding, analyzing and negotiating a transaction. The allocation of the purchase price is an area that requires judgment and significant estimates. Tangible and intangible assets include land, building and improvements, furniture, fixtures and equipment, acquired above market and below market leases, in-place lease value (if applicable). Acquisition-date fair values of assets and assumed liabilities are determined based on replacement costs, appraised values, and estimated fair values using methods similar to those used by independent appraisers and that use appropriate discount and/or capitalization rates and available market information. (Loss) Earnings Per Common Share 0 11,597 29,314 13,596 Concentration of Credit Risk - During the nine months ended September 30, 2022, one customer accounted for 13 % of our consolidated revenue. As of September 30, 2022, this same customer accounted for 35% of our consolidated trade accounts receivable balance. During the nine months ended September 30, 2021, this customer accounted for 31% of our consolidated revenue and 57% of our consolidated trade accounts receivable balance. During the nine months ended September 30, 2022, vendor 1 accounted for 43% 21% 76% Income Taxes Recent Accounting Pronouncements

Revenue

Revenue	9 Months Ended
	Sep. 30, 2022
Revenue from Contract with Customer [Abstract]
Revenue	2. Revenue The Company recognizes its products and services revenue based on when the title passes to the customer or when the service is completed and accepted by the customer. Revenue is measured as the amount of consideration the Company expects to receive in exchange for shipped product or service provided. Sales and other taxes billed and collected from customers are excluded from revenue. The Company recognizes rental income associated with its REIT, net of amortization of favorable/unfavorable lease terms relative to market and includes rental abatements and contractual fixed increases attributable to operating leases, where collection has been considered probable, on a straight-line basis over the term of the related lease. The Company recognizes net investment income from its investment banking line of business as interest owed to the Company occurs. The Company generates revenue from its direct marketing line of business primarily through internet sales and recognizes revenue as items are shipped. As of September 30, 2022, the Company had no unsatisfied performance obligations for contracts with an original expected duration of greater than one year. Pursuant to Topic 606, the Company has applied the practical expedient with respect to disclosure of the deferral and future expected timing of revenue recognition for transaction price allocated to remaining performance obligations. The Company elected the practical expedient allowing it to not recognize as a contract asset the commission paid to its salesforce on the sale of its products as an incremental cost of obtaining a contract with a customer but rather recognize such commission as expense when incurred as the amortization period of the asset that the Company would have otherwise recognized is one year or less. Accounts Receivable The Company extends credit to its customers in the normal course of business. The Company performs ongoing credit evaluations and generally does not require collateral. Payment terms are generally 30 days but up to net 105 for certain customers. The Company carries its trade accounts receivable at invoice amount less an allowance for doubtful accounts. On a periodic basis, the Company evaluates its accounts receivable and establishes an allowance for doubtful accounts based upon management’s estimates that include a review of the history of past write-offs and collections and an analysis of current credit conditions. At September 30, 2022, and December 31, 2021, the Company established a reserve for doubtful accounts of approximately $ 42,000 20,000 Sales Commissions Sales commissions are expensed as incurred for contracts with an expected duration of one year or less. There were no sales commissions capitalized as of September 30, 2022. Shipping and Handling Costs Costs incurred by the Company related to shipping and handling are included in cost of products sold. Amounts charged to customers pertaining to these costs are reflected as revenue. See Note 12 for disaggregated revenue information.

Notes Receivable

Notes Receivable	9 Months Ended
	Sep. 30, 2022
Receivables [Abstract]
Notes Receivable	3. Notes Receivable Note 1 On October 15, 2020, APB entered into a loan agreement with (“Note 1”) with Borrower 1. Note 1, not to exceed the principal sum of $ 200,000 12 October 15, 2022 0 39,000 39,000 Note 2 On February 8, 2021, the Company entered into a convertible promissory note (“Note 2”) with Borrower 2, a company registered in Gibraltar. The Company loaned the principal sum of $ 800,000 4% 0 829,000 Note 3 On February 21, 2021, Impact BioMedical, Inc. a subsidiary of the Company, entered into a promissory note (“Note 3”) with an individual. The Company loaned the principal sum of $ 206,000 6.5% February 19, 2024 206,000 197,000 16,000 190,000 Note 4, related party On May 13, 2021, and later amended in April 2022, Sentinel Brokers, LLC, a subsidiary of the Company entered a revolving credit promissory note (“Note 4”) with Borrower 4, a company registered in the state of New York, of which Sentinel Brokers, LLC., owns 24.9% 3,000,000 6.65% May 13, 2023 309,000 0 Note 5 On May 14, 2021, DSS Pure Air, Inc. a subsidiary of the Company entered into a convertible promissory note (“Note 5”) with Borrower 5, a company registered in the state of Texas. Note 5 has an aggregate principal balance up to $ 5,000,000 6.5% May 14, 2023 5,333,000 5,081,000 Note 6 On September 23, 2021, APB entered into refunding bond anticipatory note (“Note 6”) with Borrower 6, which operates as a conservation and reclamation district pursuant to Chapter 3891, Texas Special District Local Laws Code; Chapter 375, Texas Local Government Code; and Chapter 49, Texas Water Code. The District Note was in the sum of $ 3,500,000 4.15% September 22, 2022 3,645,000 5.6% 3,650,000 3,540,000 Note 7 On October 25, 2021, APB entered into loan agreement (“Note 7”) with Borrower 7, a company registered in the state of Utah. Note 7 has an initial aggregate principal balance up to $ 1,000,000 3,000,000 8.0% October 25, 2022 This note contains an optional conversion feature allowing APB to convert the outstanding principal to a 10% membership interest 937,000 784,000 Note 8 On June 13, 2019, APB extended the credit (“Note 8”) to an individual (“Borrower 8”) in the form of a promissory note for $ 250,000 15% May 15, 2020 250,000 15% May 14, 2021 250,000 12.5% May 15, 2023 256,000 260,000 Note 9, related party On October 7, 2021, HWH World, Inc., a subsidiary of the Company entered into a revolving loan commitment (“Note 9”) with Borrower 9, a company registered in Taiwan. Note 9 has an principal balance of $ 52,000 December 31,2021 61,000 52,000 Note 10 On December 28, 2021, APB entered into promissory note (“Note 10”) with Borrower 10, a company registered in the state of California. Note 10 has an principal balance of $ 700,000 12.0% December 28, 2022 759,000 700,000 Note 11 On January 24, 2022, APB and Borrower 11 entered into a promissory note (“Note 11”) in the principal sum of $ 100,000 6% 104,000 Note 12 On March 2, 2022, APB and Borrower 12, a corporation organized under the laws of the Republic of Korea entered into a promissory note (“Note 12”). Under the terms of Note 12, APB at its discretion, may lend up to the principal sum of $ 893,000 8% 887,000 446,000 Note 13 On May 9, 2022, DSS PureAir and Borrower 5 entered into a promissory note (“Note 13”) in the principal sum of $ 210,000 10% 218,000 Note 14, related party On August 29, 2022, DSS Financial Management, Inc. (“DSSFM”) entered into subordinated loan agreement (“Note 14”) with Borrower 14, a broker/dealer, of which DSSFM owns 24.9% 100,000 8% August 29, 2025 101,000 Note 15 On July 26, 2022, APB entered into a revolving credit promissory note (Note 15) with Borrower 15 for the principal sum up to $ 1,000,000 8% July 26, 2024 917,000

Financial Instruments

Financial Instruments	9 Months Ended
	Sep. 30, 2022
Investments, All Other Investments [Abstract]
Financial Instruments	4. Financial Instruments Cash, Cash Equivalents, Restricted Cash and Marketable Securities The following tables show the Company’s cash, cash equivalents, restricted cash, and marketable securities by significant investment category as of September 30, 2022, and December 31, 2021: Schedule of Cash and Marketable Securities by Significant Investment Category 2022 Adjusted Cost Unrealized Fair Cash and Marketable Investments Cash $ 21,151,000 $ - $ 21,151,000 $ 21,151,000 $ - $ - Level 1 Money Market Funds 1,694,000 - 1,694,000 1,694,000 - - Marketable Securities 32,498,000 (4,415,000 ) 28,083,000 - 28,083,000 - Investment in unconsolidated subsidiaries - - - - - - Level 2 Warrants 3,318,000 (2,246,000 ) 1,072,000 - - 1,072,000 Convertible securities 1,023,000 (725,000) 298,000 - - 298,000 Total $ 59,684,000 $ (7,386,000 ) $ 52,298,000 $ 22,845,000 $ 28,083,000 $ 1,370,000 2021 Adjusted Cost Unrealized Gain/(Loss) Fair Value Cash and Cash Equivalents Marketable Securities Investments Cash $ 50,286,000 $ - $ 50,286,000 $ 50,286,000 $ - $ - Level 1 Money Market Funds $ 6,309,000 - 6,309,000 6,309,000 - - Marketable Securities $ 12,993,000 1,544,000 14,537,000 - 14,537,000 - Level 2 Warrants $ 3,318,000 - 3,318,000 - - 3,318,000 Convertible securities $ 1,023,000 - 1,023,000 - - 1,023,000 Total $ 73,929,000 $ 1,544,000 $ 75,473,000 $ 56,595,000 $ 14,537,000 $ 4,341,000 The Company typically invests with the primary objective of minimizing the potential risk of principal loss. The Company’s investment policy generally requires securities to be investment grade and limits the amount of credit exposure to any one issuer. Fair values were determined for each individual security in the investment portfolio.

Acquisitions

Acquisitions	9 Months Ended
	Sep. 30, 2022
Business Combination and Asset Acquisition [Abstract]
Acquisitions	5. Acquisitions Sharing Services Global Corp. (“SHRG”) As of and through September 30, 2020, the Company classified its investment in Sharing Services Global Corp. (“SHRG”), a publicly traded company, as marketable equity security and measured it at fair value with gains and losses recognized in other income. In July 2020, through continued acquisition of common stock, as detailed below, the Company obtained greater than 20% Investments—Equity Method and Joint Ventures 58% 28,494,000 45,660,000 10,418,000 22,463,000 On January 24, 2022, the Company exercised 50,000,000 0.0001 65% 1,632,000 702,000 We are currently in the process of completing the purchase price accounting and related allocations associated with the acquisition of SHRG. The Company is in the process of completing valuations and useful lives for certain assets acquired in the transaction. We expect the preliminary purchase price accounting to be completed during the year ending December 31, 2022.

Investments

Investments	9 Months Ended
	Sep. 30, 2022
Investments, All Other Investments [Abstract]
Investments	6. Investments Alset International Limited related party The Company owns 127,179,311 4% 3,370,000 4,909,000 1,539,000 967,000 West Park Capital, Inc. On October 10, 2019, the Company entered into a convertible promissory note (“TBD Note”) with Century TBD Holdings, LLC (“TBD”), a Florida limited liability company. The Company loaned the principal sum of $ 500,000 500,000 19.8% 6% October 9, 2021 537,000 7.5% 500,000 37,000 BMI Capital International LLC On September 10, 2020, the Company’s wholly owned subsidiary DSS Securities, Inc. entered into membership interest purchase agreement with BMI Financial Group, Inc. a Delaware corporation (“BMIF”) and BMI Capital International LLC, a Texas limited liability company (“BMIC”) whereas DSS Securities, Inc. purchased 14.9% 100,000 10% 100,000 24.9% 20% 10,000 BMIC is a broker-dealer registered with the Securities and Exchange Commission, is a member of the Financial Industry Regulatory Authority, Inc. (“FINRA”), and is a member of the Securities Investor Protection Corporation (“SIPC”). The Company’s chairman of the board and another independent board member of the Company also have ownership interest in BMIC. BioMed Technologies Asia Pacific Holdings Limited On December 19, 2020, Impact BioMedical, a wholly owned subsidiary of the Company, entered into a subscription agreement (the “Subscription Agreement”) with BioMed Technologies Asia Pacific Holdings Limited (“BioMed”), a limited liability company incorporated in the British Virgin Islands, pursuant to which the Company agreed to purchase 525 4.99% 632,000 BioMed focuses on manufacturing natural probiotics, pursuant to which the Company will directly market, advertise, promote, distribute and sell certain BioMed products to resellers. The products to be distributed by the Company include BioMed’s PGut Premium Probiotics ® ® ® ® ® Under the terms of the Distribution Agreement, the Company will have exclusive rights to distribute the products within the United States, Canada, Singapore, Malaysia, and South Korea and non-exclusive distribution rights in all other countries. In exchange, the Company agreed to certain obligations, including mutual marketing obligations to promote sales of the products. This agreement is for ten years with a one year auto-renewal feature. Vivacitas Oncology, Inc. On March 15, 2021, the Company, through one of its subsidiaries, entered into a Stock Purchase Agreement (the “Vivacitas Agreement #1”) with Vivacitas Oncology Inc. (“Vivacitas”), to purchase 500,000 1.00 1,500,000 1.00 500,000 2,480,000 2,480,000 250,000 On April 1, 2021, the Company entered into an additional stock purchase agreement with Vivacitas (“Vivacitas Agreement #2”), whereas Vivacities wished to employ the service of the Chief Business Officer of Impact Biomedical, and in return for the services of this individual, Vivacitas shall issue to the Company, the aggregate purchase price for the Class A Common Shares of Vivacitas at the value of $1.00 per share shall be $ 120,000 On July 22, 2021, the Company exercised 1,000,000 1,000,000 120,000 16% 4,100,000 4,035,000 Sentinel Brokers Company, Inc. On May 13, 2021, a Sentinel Brokers, LLC., subsidiary of the Company entered into a stock purchase agreement (“Sentinel Agreement”) to acquire a 24.9 300,000 750,000 1,050,000 50.1 25% 50.1% Investments—Equity Method and Joint Ventures 24.9 143,000 Sentinel is a broker-dealer operating primarily as a fiduciary intermediary, facilitating intuitional trading of municipal and corporate bonds as well as preferred stock, and is registered with the Securities and Exchange Commission, is a member of the Financial Industry Regulatory Authority, Inc. (“FINRA”), and is a member of the Securities Investor Protection Corporation (“SIPC”). Stemtech Corporation In September 2021, the Company, Stemtech Corporation (“Stemtech”) and Globe Net Wireless Corp. (“GNTW”) entered into a Securities Purchase Agreement (the “SPA”) pursuant to which the Company invested $ 1.4 1.4 500,000 10% 1.4 154,173 The Company carries its investment in the Convertible Note, the GNTW Warrant and the shares of GNTW common stock at fair value in accordance with GAAP. During the three and six months ended September 30, 2022, the Company recognized losses, before income tax, of $ 8.6 3.7 MojiLife, LLC In September 2021, the Company entered into a Membership Unit Purchase Agreement pursuant to which the Company acquired a 30.75% 1,537,000

Short-Term and Long-Term Debt

Short-Term and Long-Term Debt	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Short-Term and Long-Term Debt	7. Short-Term and Long-Term Debt DSS, Inc Promissory Notes - 200,000 8.0% 5.00 200,000 On March 16, 2021, American Medical REIT, Inc. received loan proceeds in the amount of approximately $ 110,000 1% 111,000 On May 20, 2021, Premier Packaging entered into master loan and security agreement (“BOA Note”) with Bank of America, N.A. (“BOA”) to secure financing approximating $ 3,710,000 3,521,000 3,339,000 4.63 468,000 3,053,000 On June 18, 2021, AMRE Shelton, LLC., (“AMRE Shelton”) a subsidiary of AMRE, entered into a loan agreement (“Shelton Agreement”) with Patriot Bank, N.A. (“Patriot Bank”) in an amount up to $ 6,155,000 5,105,000 4.25 %. The interest will be adjusted commencing on July 1, 2026 and continuing for the next succeeding 5 year period shall be determined one month prior to the change date and shall be an interest rate equal to two hundred fifty (250) basis points above the Federal Home Loan Bank Boston 5-Year/25-Year amortizing advance rate, but in no event less than 4.25 % for the term of 120 months with a balloon payment approximating $ 2,829,000 due at term end. The funds borrowed were used to purchase a 40,000 square foot, 2.0 story, Class A+ multi-tenant medical office building located on a 13.62 acre site (See Note 5). As of September 30, 2022, the total balance due net of deferred financing costs of $ 79,000 4,821,000 216,000 4,605,000 On October 13, 2021, LVAM entered into loan agreement with BMIC (“BMIC Loan”), a related party, whereas LVAM borrowed the principal amount of $ 3,000,000 October 12, 2022 3,068,000 3,000,000 On October 13, 2021, LVAM entered into loan agreement with Lee Wilson Tsz Kin (“Wilson Loan”), a related party, whereas LVAM borrowed the principal amount of $ 3,000,000 3,000,000 On November 2, 2021, AMRE LifeCare entered into a loan agreement (“LifeCare Agreement”) with Pinnacle Bank, (“Pinnacle Bank”) in the amount of $ 40,300,000 . The LifeCare Agreement calls for the principal amount of the in equal, consecutive monthly installments based upon a twenty-five ( 25 ) year amortization of the original principal amount of the LifeCare Agreement at an initial rate of interest equal to the interest rate determined in accordance as of July 29, 2022 provided, however, such rate of interest shall not be less than 4.28%, with the first such installment being payable on August 29, 2022 and subsequent installments being payable on the first day of each succeeding month thereafter until the maturity date, at which time any outstanding principal and interest is due in full. The maturity date of November 2, 2023, may be extended to November 2, 2024 . As of December 31, 2021, the outstanding principal and interest of the LifeCare agreement approximates $ 39,448,000 , net of deferred financing costs of $ 1,002,000 . As of September 30, 2022, the outstanding principal and interested, net of deferred financing costs of $ 352,000 approximates $ 40,133,000 is included in Current portion of long-term debt, on the consolidated balance sheet. This agreement contains certain covenants that are analyzed on an annual basis, starting December 31, 2021 At September 30, 2022, AMRE is in compliance with all covenants. In November 2021, AMRE entered into a convertible promissory note (“Alset Note”) with Alset International Limited (“Alset International”), a related party, for the principal amount of $ 8,350,000 8% 8,805,000 21,366,177 8,350,000 367,000 On March 17, 2022, AMRE Winter Haven, LLC (“AMRE Winter Haven”) and Pinnacle Bank (“Pinnacle”) entered into a term loan (“Pinnacle Loan”) whereas Pinnacle lent to AMRE Winter Haven the principal sum of $ 2,990,000 March 7, 2024 4.28% 104,000 2,904,000 Sharing Services Global Corporation In October 2017, Sharing Services issued a Convertible Promissory Note in the principal amount of $ 50,000 333,333 333,333 0.15 78,635.62 In December 2019, SHRG and the holder of the SHRG $ 100,000

Lease Liability

Lease Liability	9 Months Ended
	Sep. 30, 2022
Lease Liability
Lease Liability	8. Lease Liability The Company has operating leases predominantly for operating facilities. As of September 30, 2022, the remaining lease terms on our operating leases range from less than one to twelve years. Renewal options to extend our leases have not been exercised due to uncertainty. Termination options are not reasonably certain of exercise by the Company. There is no transfer of title or option to purchase the leased assets upon expiration. There are no residual value guarantees or material restrictive covenants. There are no significant finance leases as of September 30, 2022. Future minimum lease payments as of September 30, 2022, are as follows: Maturity of Lease Liability: Schedule of Future Minimum Lease Payments Totals 2022 284,000 2023 1,132,000 2024 908,000 2025 877,000 2026 890,000 2027 904,000 After 5,768,000 Total lease payments 10,763,000 Less: Imputed Interest (1,953,000 ) Present value of remaining lease payments $ 8,810,000 Current $ 819,000 Noncurrent $ 7,991,000 Weighted-average remaining lease term (years) 14.9 Weighted-average discount rate 4.3 % In March of 2022, Premier Packaging began leasing its relocated manufacturing facilities to West Henrietta, New York. This lease contains an escalating payment clause, ranging from $ 61,000 78,000

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	9. Commitments and Contingencies The Ronaldi Litigation In April 2019 DSS commenced an action in New York State Supreme Court, Monroe County, Index No. E2019003542, against Jeffrey Ronaldi, our former Chief Executive Officer. The New York action sought a declaratory judgment that, contrary to informal claims made by him, Mr. Ronaldi’s employment agreement with us expired by its terms and that he is not entitled to any cash bonuses or other unpaid amounts. The lawsuit also sought an injunction against Mr. Ronaldi from interfering with any of DSS’ IP litigation. Mr. Ronaldi subsequently commenced an action against DSS in the Superior Court of California, County of San Diego, on November 8, 2019, under case number 37-2019-00059664-CU-CO-CTL, in which he alleged that DSS terminated his employment in April 2019 in order to avoid paying him certain employment-related amounts. DSS was successful in dismissing the California case and consolidating it with the action pending in Monroe County, New York. Mr. Ronaldi asserted counterclaims in the Monroe County, New York action similar to those he originally brought in California. Mr. Ronaldi claimed that his termination violated an alleged employment agreement or implied-in-fact employment agreement and that he should have remained employed through 2019. Mr. Ronaldi seeks to recover: (i) $ 144,658 769 15,385 3,077 26,077 91,000 300,000 100,000 450,000 Additionally, on March 2, 2020, DSS and DSSTM filed a second litigation action against Jeffrey Ronaldi in the State of New York, Supreme Court, County of Monroe, Document Security Systems, Inc. and DSS Technology Management, Inc. vs. Jeffrey Ronaldi, Index No.: 2020002300, alleging acts of self-dealing and conflicts of interest while he served as CEO of both DSS and DSS TM. Mr. Ronaldi filed a Notice of Removal of this civil litigation to the United States District Court for the Western District of New York where it was assigned Case No. 6:20-cv-06265-EAW. Both pieces of Ronaldi litigation were settled and were discontinued with prejudice as of October 19, 2022. Maiden Biosciences Litigation On February 15, 2021, Maiden Biosciences, Inc. (“Maiden”) commenced an action against DSS, Inc. (“DSS”), Decentralized Sharing Systems, Inc. (“Decentralized”), HWH World, Inc. (“HWH”), RBC Life International, Inc. (RBC International) (together, the “DSS Defendants”), Frank D. Heuszel (“Heuszel”), RBC Life Sciences, Inc (“RBC”), Steven E. Brown, Clinton Howard, and Andrew Howard (collectively, “Defendants”). The lawsuit is currently pending in the United States District Court Northern District of Texas, Dallas Division, and is styled and numbered Maiden Biosciences, Inc. v. Document Security Stems, Inc., et al., Case No. 3:21-cv-00327. This lawsuit relates to two promissory notes executed by RBC in the 4 th 1,000,000 4,329,000 On March 30, 2021, Defendants DSS, Decentralized, HWH, RBC International, and Heuszel filed a motion to dismiss seeking to dismiss Maiden’s unjust enrichment, exemplary damages, and RICO claims against DSS, Decentralized, HWH, RBC Life International, Inc., and Heuszel, as well as Maiden’s fraudulent transfer claims against DSS and RBC International. On August 9, 2021, the Court then entered an order granting in part the motion to dismiss filed on behalf of DSS, Decentralized, HWH, RBC International, and Heuszel. Among other things, the Court held that Maiden failed to plausibly plead certain causes of action, including (1) the civil RICO claim against DSS, Decentralized, HWH, RBC International, and Heuszel, (2) the TUFTA claim against DSS, and (3) the unjust enrichment claim against DSS and RBC International. Notably, the Court declined the request to dismiss the TUFTA claim against RBC International. On September 3, 2021, Maiden filed its first amended complaint, asserting a single cause of action against the DSS Defendants, Heuszel, and RBC for an alleged TUFTA violation. Generally, Maiden sought the same relief requested in its original complaint. Maiden, however, abandoned its request for treble damages. On September 17, 2021, the DSS Defendants filed a motion to dismiss the amended complaint seeking to dismiss Maiden’s TUFTA claim to the extent it seeks to avoid a transfer of assets owned by any of RBC’s subsidiaries, including but not limited to RBC Life Sciences USA, Inc. (“RBC USA”). Further, the motion to dismiss sought the dismissal of Maiden’s TUFTA claim against Heuszel. On November 19, 2021, the Court granted the motion to dismiss in part, dismissing Maiden’s claim against Heuszel and determined Maiden failed to plead that it was a creditor of RBC USA or RBC’s other subsidiaries. However, the Court permitted Maiden to replead once again. On December 17, 2021, Maiden filed its second amended complaint which now asserts a single TUFTA claim against only the DSS Defendants, RBC, and RBC USA. During the discovery period, the Parties conducted written discovery, production of documents, and depositions of fact witnesses and expert witnesses. The discovery period closed on August 9, 2022. The DSS Defendants have engaged Stout Risius Ross, LLC to provide expert opinions regarding the value of the assets at issue. On August 15, 2022, the DSS Defendants filed a motion to exclude Maiden’s designated expert. The DSS Defendants’ motion to exclude is still before the Court for determination. Currently, the Company is preparing for trial which is set for December 5, 2022 on the Court’s two-week docket. The Company intends to vigorously defend its position at trial that Maiden should recover nothing on account of its TUFTA claim. In addition to the foregoing, we may become subject to other legal proceedings that arise in the ordinary course of business and have not been finally adjudicated. Adverse decisions in any of the foregoing may have a material adverse effect on our results of operations, cash flows or our financial condition. The Company accrues for potential litigation losses when a loss is probable and estimable. License Agreement On March 19, 2022, Impact BioMedical entered into a License Agreement (“Equivir License”) with a third-party (“Licensee”) where the Licensor is granted the right, amongst other things, to develop, commercialize, and sell the Company’s Equivir technology. In exchange, the Licensee shall pay the Company a royalty of 5.5 1,250,000

Stockholders_ Equity

Stockholders’ Equity	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Stockholders’ Equity	10. Stockholders’ Equity Sales of Equity On February 28, 2022, DSS entered into an Amendment to Stock Purchase Agreement (the “Amendment”) with its shareholder Alset EHome International Inc. (“AEI”), pursuant to which the Company and AEI have agreed to amend certain terms of the Stock Purchase Agreement dated January 25, 2022 (the “SPA”). Pursuant to the SPA, AEI had agreed to purchase up to 44,619,423 0.3810 17,000,000 3,986,877 1,519,000 On March 10, 2022, the Company issued 894,084 340,000 On May 5, 2022, the Company issued 63,205 29,000 On May 25, 2022, the Company issued 15,389,995 5,847,000 On May 17, 2022, the shareholders of the Company approved the issuance of up to 21,366,177 8,350,000 367,000 On May 17, 2022, the shareholders of the Company approved the acquisition of 62,122,908 17,570,948 Stock-Based Compensation - 4,000 .

Supplemental Cash Flow Informat

Supplemental Cash Flow Information	9 Months Ended
	Sep. 30, 2022
Supplemental Cash Flow Elements [Abstract]
Supplemental Cash Flow Information	11. Supplemental Cash Flow Information The following table summarizes supplemental cash flows for the nine-months ended September 30, 2022, and 2021: Schedule of Supplemental Cash Flow Information 2022 2021 Cash paid for interest $ 1,907,000 $ 139,000 Non-cash investing and financing activities: Termination of right of use lease asset $ - $ (744,000 ) Termination of right of use lease liability $ - $ 744,000 Shares received for loan origination fee $ - $ (3,000,000 ) Shares received for prepaid loan interest $ - $ (2,440,000 ) Notes receivable converted to equity investments $ 1,940,000 $ - Shares issued for the acquisition of marketable securities $ 7,169,000 $ - Shares issued for the acquisition of notes receivable $ 8,717,000 $ - Right of use asset addition $ 9,895,000 $ - Shares issued in lieu of bonus cash $ 6,216,000 $ -

Segment Information

Segment Information	9 Months Ended
	Sep. 30, 2022
Segment Reporting [Abstract]
Segment Information	12. Segment Information The Company’s nine businesses lines are organized, managed and internally reported as five Our segment structure presented below represents a change from the prior year for the inclusion of our Biotechnology, Securities, and Commercial Lending segments and the removal of our Plastics segment, Digital Group and IP Technology Management segment as the Plastics segment was discontinued in 2020, DSS Digital was sold and discontinued in May 2021 and activities surrounding our IP Technology Management segment have significantly decreased. The amounts for these segments have been included in the Corporate reporting segment for the three and nine months ended September 30, 2022 and 2021, as necessary, below for reconciliation purposes. Approximate information concerning the Company’s operations by reportable segment for the three and nine months ended September 30, 2022 and 2021 is as follows. The Company relies on intersegment cooperation and management does not represent that these segments, if operated independently, would report the results contained herein: Schedule of Operations by Reportable Segment Three Months Ended September 30, 2022 Product Packaging Commercial Lending Direct Marketing Biotechnology Securities Corporate Total Revenue $ 4,707,000 $ 370,000 $ 4,956,000 $ - $ 1,646,000 $ 183,000 $ 11,862,000 Depreciation and amortization 168,000 - 41,000 278,000 2,423,000 17,000 2,927,000 Interest expense 42,000 - 193,000 - 371,000 - 606,000 Interest income - - 3,000 94,000 79,000 143,000 319,000 Net income (loss) from continuing operations (1,077,000 ) 221,000 (15,379,000 ) (909,000 ) (3,182,000 ) (4,475,000 ) (24,801,000 ) Capital expenditures 300,000 - 73,000 - - - 373,000 Identifiable assets 24,035,000 48,121,000 39,979,000 57,225,000 81,766,000 13,754,000 264,880,000 Three Months Ended September 30,2021 Product Packaging Commercial Lending Direct Marketing Biotechnology Securities Corporate Total Revenue $ 3,416,000 $ - $ 966,000 $ - $ 184,000 $ - $ 4,566,000 Depreciation and amortization 152,000 - 100,000 278,000 135,000 74,000 739,000 Interest expense 11,000 - - - 37,000 (17,000 ) 31,000 Stock based compensation 1,000 - - - - 12,000 13,000 Income tax benefit - - - - - 1,624,000 1,624,000 Net income (loss) from continuing operations 358,000 64,000 (1,304,000 ) (647,000 ) (835,000 ) (4,311,000 ) (6,675,000 ) Capital expenditures 1,399,000 - - - 186,000 55,000 1,640,000 Identifiable assets 24,752,000 60,388,000 43,695,000 55,848,000 11,376,000 23,017,000 219,076,000 Nine Months Ended September 30, 2022 Product Packaging Commercial Lending Direct Marketing Biotechnology Securities Corporate Total Revenue $ 11,876,000 $ 644,000 $ 18,000,000 $ 94,000 $ 4,817,000 $ 496,000 $ 35,927,000 Depreciation and amortization 525,000 - 248,000 835,000 7,637,000 106,000 9,351,000 Interest expense 100,000 - 193,000 - 1,812,000 - 2,105,000 Stock based compensation 1,000 - - - - 3,000 4,000 Net income (loss) from continuing operations (755,000 ) 638,000 (19,102,000 ) (2,198,000 ) (8,334,000 ) (9,410,000 ) (39,161,000 ) Capital expenditures 1,242,000 - 88,000 - 15,000 4,000 1,349,000 Identifiable assets 24,035,000 48,121,000 39,979,000 57,225,000 81,766,000 13,754,000 264,880,000 Nine Months Ended September 30,2021 Product Packaging Commercial Lending Direct Marketing Biotechnology Securities Corporate Total Revenue $ 10,652,000 $ - $ 2,382,000 $ - $ 184,000 $ - $ 13,218,000 Depreciation and amortization 459,000 - 419,000 835,000 134,000 228,000 2,075,000 Interest expense 49,000 - 2,000 1,000 87,000 18,000 157,000 Stock based compensation 2,000 - - - - 40,000 42,000 Income tax benefit - - - - - 4,315,000 4,315,000 Net income (loss) from continuing operations 641,000 64,000 (9,088,000 ) (1,955,000 ) (1,066,000 ) (10,058,000 ) (21,462,000 ) Capital expenditures 2,621,000 - 6,000 - 6,750,000 4,000 9,381,000 Identifiable assets 24,752,000 60,388,000 43,695,000 55,848,000 11,376,000 23,017,000 219,076,000 The following tables disaggregate our business segment revenues by major source: Schedule of Disaggregation of Revenue Printed Products Revenue Information: Three months ended September 30, 2022 Packaging Printing and Fabrication $ 4,888,000 Commercial and Security Printing 144,000 Total Printed Products $ 5,032,000 Three months ended September 30, 2021 Packaging Printing and Fabrication $ 3,373,000 Commercial and Security Printing 43,000 Total Printed Products $ 3,416,000 Nine months ended September 30, 2022 Packaging Printing and Fabrication $ 12,357,000 Commercial and Security Printing 293,000 Total Printed Products $ 12,650,000 Nine months ended September 30, 2021 Packaging Printing and Fabrication $ 10,428,000 Commercial and Security Printing 224,000 Total Printed Products $ 10,652,000 Direct Marketing Three months ended September 30, 2022 Direct Marketing Internet Sales $ 4,937,000 Total Direct Marketing $ 4,937,000 Three months ended September 30, 2021 Direct Marketing Internet Sales $ 966,000 Total Direct Marketing $ 966,000 Nine months ended September 30, 2022 Direct Marketing Internet Sales $ 17,939,000 Total Direct Marketing $ 17,939,000 Nine months ended September 30, 2021 Direct Marketing Internet Sales $ 2,382,000 Total Direct Marketing $ 2,382,000 Rental Income Three months ended September 30, 2022 Rental income $ 1,485,000 Total Rental Income $ 1,485,000 Three months ended September 30, 2021 Rental income $ 184,000 Total Rental Income $ 184,000 Nine months ended September 30, 2022 Rental income $ 4,656,000 Total Rental Income $ 4,656,000 Nine months ended September 30, 2021 Rental income $ 184,000 Total Rental Income $ 184,000 Management Fee Income Three months ended September 30, 2022 Management fee income $ 38,000 Total Rental Income $ 38,000 Three months ended September 30, 2021 Management fee income $ - Total Rental Income $ - Nine months ended September 30, 2022 Management fee income $ 38,000 Total Management fee income $ 38,000 Nine months ended September 30, 2021 Management fee income $ - Total Management fee income $ - Net Investment Income Three months ended September 30, 2022 Net Investment Income $ 370,000 Total Investment Income $ 370,000 Three months ended September 30, 2021 Net Investment Income $ - Total Rental Income $ - Nine months ended September 30, 2022 Net investment income $ 644,000 Total Management fee income $ 644,000 Nine months ended September 30, 2021 Net Investment Income $ - Total Management fee income $ -

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2022
Related Party Transactions [Abstract]
Related Party Transactions	13. Related Party Transactions The Company owns 127,179,311 4 3,370,000 4,909,000 1,539,000 967,000 On March 2, 2020, AMRE entered into a $ 200,000 8.0% 5.00 200,000 On March 18, 2021, the Company entered into an agreement with Alset EHome International, Inc. (“Seller”), a related party, to purchase from the Seller’s its wholly owned subsidiary Impact Oncology PTE Ltd. (“IOPL”) for a purchase price $ 2,480,000 2,480,000 250,000 On or about August 28, 2020, the Company’s wholly owned subsidiary, DSS Securities, Inc. entered into a corporate venture to form and operate a real estate title agency, under the name of Alset Title Company, Inc, a Texas corporation (“ATC”). DSS Securities, Inc. shall own 70% of this venture with the other two shareholders being attorneys necessary to the state application and permitting process. The Company’s CEO, who is a licensed attorney, has a stated non-compensated 15% ownership interest in the venture. There was minimal activity for the nine months ended September 30, 2022 On September 9, 2021, the Company finalized a stock purchase agreement (the “SPA”) with American Pacific Bancorp (“APB”), which provided for an investment of $ 40,000,000 6,666,700 0.01 6.00 53 36,000 645,000 306,000 2 On October 7, 2021, HWH World, Inc., a subsidiary of the Company entered into a revolving loan commitment (“Note 9”) with Borrower 9, a company registered in Taiwan. Note 9 has an principal balance of $ 52,000 December 31,2021 61,000 52,000 On October 13, 2021, LVAM entered into loan agreement with BMIC (“BMIC Loan”), a related party, whereas LVAM borrowed the principal amount of $ 3,000,000 October 12, 2022 3,068,000 3,000,000 On October 13, 2021, LVAM entered into loan agreement with Lee Wilson Tsz Kin (“Wilson Loan”), a related party, whereas LVAM borrowed the principal amount of $ 3,000,000 October 12, 2022 3,000,000 In November 2021, AMRE entered into a convertible promissory note (“Alset Note”) with Alset International Limited (“Alset International”), a related party, for the principal amount of $ 8,350,000 December 2023, with interest due quarterly and the principal due at maturity 8,805,000 21,366,177 8,350,000 367,000 On February 28, 2022, DSS entered into an Amendment to Stock Purchase Agreement (the “Amendment”) with its shareholder Alset EHome International Inc. (“AEI”), pursuant to which the Company and AEI have agreed to amend certain terms of the Stock Purchase Agreement dated January 25, 2022 (the “SPA”). Pursuant to the SPA, AEI had agreed to purchase 44,619,423 0.3810 17,000,000 3,986,877 1,519,000 On May 13, 2021, and later amended in April 2022, Sentinel Brokers, LLC, a subsidiary of the Company entered a revolving credit promissory note (“Note 4”) with Borrower 4, a company registered in the state of New York and related party. Note 4 has an aggregate principal balance up to $ 3,000,000 6.65% May 13, 2023 309,000 0 1,364,000 13.64 In October 2017, Sharing Services issued a Convertible Promissory Note in the principal amount of $ 50,000 333,333 333,333 0.15 78,635.62 On May 17, 2022, the shareholders of the Company approved the issuance of up to 21,366,177 8,350,000 367,400 On May 17, 2022, the shareholders of the Company approved the acquisition of 62,122,908 17,570,948 0.34

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2022
Subsequent Events [Abstract]
Subsequent Events	14. Subsequent Events On October 20, 2022, Sentinel Brokers, LLC. entered into an on demand promissory note with Borrower 4, a related party, in the amount of $ 1,000,000 8%

Basis of Presentation and Sig_2

Basis of Presentation and Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Principles of Consolidation	Principles of Consolidation
Use of Estimates	Use of Estimates
Reclassifications	Reclassifications
Cash Equivalents	Cash Equivalents
Notes receivable, unearned interest, and related recognition	Notes receivable, unearned interest, and related recognition
Investments	Investments For equity method investments, the Company regularly reviews its investments to determine whether there is a decline in fair value below book value. If there is a decline that is other-than-temporary, the investment is written down to fair value. See Note 6 for further discussion on investments.
Fair Value of Financial Instruments	Fair Value of Financial Instruments - ● Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets. ● Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and ● Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. The carrying amounts reported in the consolidated balance sheet of cash and cash equivalents, accounts receivable, prepaids, accounts payable and accrued expenses approximate fair value because of the immediate or short-term maturity of these financial instruments. Marketable securities classify as a Level 1 fair value financial instrument. The fair value of notes receivable approximates their carrying value as the stated or discounted rates of the notes do not reflect recent market conditions. The fair value of revolving credit lines notes payable and long-term debt approximates their carrying value as the stated or discounted rates of the debt reflect recent market conditions. The fair value of investments where the fair value is not considered readily determinable, are carried at cost.
Inventory	Inventory 434,000 388,000
Impairment of Long-Lived Assets and Goodwill	Impairment of Long-Lived Assets and Goodwill
(Loss) Earnings Per Common Share	Acquisitions Acquisition of assets are recorded at their relative fair value based on total accumulated costs of the acquisition. Direct acquisition-related costs are capitalized as a component of the acquired assets. This includes all costs related to finding, analyzing and negotiating a transaction. The allocation of the purchase price is an area that requires judgment and significant estimates. Tangible and intangible assets include land, building and improvements, furniture, fixtures and equipment, acquired above market and below market leases, in-place lease value (if applicable). Acquisition-date fair values of assets and assumed liabilities are determined based on replacement costs, appraised values, and estimated fair values using methods similar to those used by independent appraisers and that use appropriate discount and/or capitalization rates and available market information. (Loss) Earnings Per Common Share 0 11,597 29,314 13,596
Concentration of Credit Risk	Concentration of Credit Risk - During the nine months ended September 30, 2022, one customer accounted for 13 % of our consolidated revenue. As of September 30, 2022, this same customer accounted for 35% of our consolidated trade accounts receivable balance. During the nine months ended September 30, 2021, this customer accounted for 31% of our consolidated revenue and 57% of our consolidated trade accounts receivable balance. During the nine months ended September 30, 2022, vendor 1 accounted for 43% 21% 76%
Income Taxes	Income Taxes
Recent Accounting Pronouncements	Recent Accounting Pronouncements

Financial Instruments (Tables)

Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2022
Investments, All Other Investments [Abstract]
Schedule of Cash and Marketable Securities by Significant Investment Category	The following tables show the Company’s cash, cash equivalents, restricted cash, and marketable securities by significant investment category as of September 30, 2022, and December 31, 2021: Schedule of Cash and Marketable Securities by Significant Investment Category 2022 Adjusted Cost Unrealized Fair Cash and Marketable Investments Cash $ 21,151,000 $ - $ 21,151,000 $ 21,151,000 $ - $ - Level 1 Money Market Funds 1,694,000 - 1,694,000 1,694,000 - - Marketable Securities 32,498,000 (4,415,000 ) 28,083,000 - 28,083,000 - Investment in unconsolidated subsidiaries - - - - - - Level 2 Warrants 3,318,000 (2,246,000 ) 1,072,000 - - 1,072,000 Convertible securities 1,023,000 (725,000) 298,000 - - 298,000 Total $ 59,684,000 $ (7,386,000 ) $ 52,298,000 $ 22,845,000 $ 28,083,000 $ 1,370,000 2021 Adjusted Cost Unrealized Gain/(Loss) Fair Value Cash and Cash Equivalents Marketable Securities Investments Cash $ 50,286,000 $ - $ 50,286,000 $ 50,286,000 $ - $ - Level 1 Money Market Funds $ 6,309,000 - 6,309,000 6,309,000 - - Marketable Securities $ 12,993,000 1,544,000 14,537,000 - 14,537,000 - Level 2 Warrants $ 3,318,000 - 3,318,000 - - 3,318,000 Convertible securities $ 1,023,000 - 1,023,000 - - 1,023,000 Total $ 73,929,000 $ 1,544,000 $ 75,473,000 $ 56,595,000 $ 14,537,000 $ 4,341,000

Lease Liability (Tables)

Lease Liability (Tables)	9 Months Ended
	Sep. 30, 2022
Lease Liability
Schedule of Future Minimum Lease Payments	Future minimum lease payments as of September 30, 2022, are as follows: Maturity of Lease Liability: Schedule of Future Minimum Lease Payments Totals 2022 284,000 2023 1,132,000 2024 908,000 2025 877,000 2026 890,000 2027 904,000 After 5,768,000 Total lease payments 10,763,000 Less: Imputed Interest (1,953,000 ) Present value of remaining lease payments $ 8,810,000 Current $ 819,000 Noncurrent $ 7,991,000 Weighted-average remaining lease term (years) 14.9 Weighted-average discount rate 4.3 %

Supplemental Cash Flow Inform_2

Supplemental Cash Flow Information (Tables)	9 Months Ended
	Sep. 30, 2022
Supplemental Cash Flow Elements [Abstract]
Schedule of Supplemental Cash Flow Information	The following table summarizes supplemental cash flows for the nine-months ended September 30, 2022, and 2021: Schedule of Supplemental Cash Flow Information 2022 2021 Cash paid for interest $ 1,907,000 $ 139,000 Non-cash investing and financing activities: Termination of right of use lease asset $ - $ (744,000 ) Termination of right of use lease liability $ - $ 744,000 Shares received for loan origination fee $ - $ (3,000,000 ) Shares received for prepaid loan interest $ - $ (2,440,000 ) Notes receivable converted to equity investments $ 1,940,000 $ - Shares issued for the acquisition of marketable securities $ 7,169,000 $ - Shares issued for the acquisition of notes receivable $ 8,717,000 $ - Right of use asset addition $ 9,895,000 $ - Shares issued in lieu of bonus cash $ 6,216,000 $ -

Segment Information (Tables)

Segment Information (Tables)	9 Months Ended
	Sep. 30, 2022
Segment Reporting [Abstract]
Schedule of Operations by Reportable Segment	Approximate information concerning the Company’s operations by reportable segment for the three and nine months ended September 30, 2022 and 2021 is as follows. The Company relies on intersegment cooperation and management does not represent that these segments, if operated independently, would report the results contained herein: Schedule of Operations by Reportable Segment Three Months Ended September 30, 2022 Product Packaging Commercial Lending Direct Marketing Biotechnology Securities Corporate Total Revenue $ 4,707,000 $ 370,000 $ 4,956,000 $ - $ 1,646,000 $ 183,000 $ 11,862,000 Depreciation and amortization 168,000 - 41,000 278,000 2,423,000 17,000 2,927,000 Interest expense 42,000 - 193,000 - 371,000 - 606,000 Interest income - - 3,000 94,000 79,000 143,000 319,000 Net income (loss) from continuing operations (1,077,000 ) 221,000 (15,379,000 ) (909,000 ) (3,182,000 ) (4,475,000 ) (24,801,000 ) Capital expenditures 300,000 - 73,000 - - - 373,000 Identifiable assets 24,035,000 48,121,000 39,979,000 57,225,000 81,766,000 13,754,000 264,880,000 Three Months Ended September 30,2021 Product Packaging Commercial Lending Direct Marketing Biotechnology Securities Corporate Total Revenue $ 3,416,000 $ - $ 966,000 $ - $ 184,000 $ - $ 4,566,000 Depreciation and amortization 152,000 - 100,000 278,000 135,000 74,000 739,000 Interest expense 11,000 - - - 37,000 (17,000 ) 31,000 Stock based compensation 1,000 - - - - 12,000 13,000 Income tax benefit - - - - - 1,624,000 1,624,000 Net income (loss) from continuing operations 358,000 64,000 (1,304,000 ) (647,000 ) (835,000 ) (4,311,000 ) (6,675,000 ) Capital expenditures 1,399,000 - - - 186,000 55,000 1,640,000 Identifiable assets 24,752,000 60,388,000 43,695,000 55,848,000 11,376,000 23,017,000 219,076,000 Nine Months Ended September 30, 2022 Product Packaging Commercial Lending Direct Marketing Biotechnology Securities Corporate Total Revenue $ 11,876,000 $ 644,000 $ 18,000,000 $ 94,000 $ 4,817,000 $ 496,000 $ 35,927,000 Depreciation and amortization 525,000 - 248,000 835,000 7,637,000 106,000 9,351,000 Interest expense 100,000 - 193,000 - 1,812,000 - 2,105,000 Stock based compensation 1,000 - - - - 3,000 4,000 Net income (loss) from continuing operations (755,000 ) 638,000 (19,102,000 ) (2,198,000 ) (8,334,000 ) (9,410,000 ) (39,161,000 ) Capital expenditures 1,242,000 - 88,000 - 15,000 4,000 1,349,000 Identifiable assets 24,035,000 48,121,000 39,979,000 57,225,000 81,766,000 13,754,000 264,880,000 Nine Months Ended September 30,2021 Product Packaging Commercial Lending Direct Marketing Biotechnology Securities Corporate Total Revenue $ 10,652,000 $ - $ 2,382,000 $ - $ 184,000 $ - $ 13,218,000 Depreciation and amortization 459,000 - 419,000 835,000 134,000 228,000 2,075,000 Interest expense 49,000 - 2,000 1,000 87,000 18,000 157,000 Stock based compensation 2,000 - - - - 40,000 42,000 Income tax benefit - - - - - 4,315,000 4,315,000 Net income (loss) from continuing operations 641,000 64,000 (9,088,000 ) (1,955,000 ) (1,066,000 ) (10,058,000 ) (21,462,000 ) Capital expenditures 2,621,000 - 6,000 - 6,750,000 4,000 9,381,000 Identifiable assets 24,752,000 60,388,000 43,695,000 55,848,000 11,376,000 23,017,000 219,076,000
Schedule of Disaggregation of Revenue	The following tables disaggregate our business segment revenues by major source: Schedule of Disaggregation of Revenue Printed Products Revenue Information: Three months ended September 30, 2022 Packaging Printing and Fabrication $ 4,888,000 Commercial and Security Printing 144,000 Total Printed Products $ 5,032,000 Three months ended September 30, 2021 Packaging Printing and Fabrication $ 3,373,000 Commercial and Security Printing 43,000 Total Printed Products $ 3,416,000 Nine months ended September 30, 2022 Packaging Printing and Fabrication $ 12,357,000 Commercial and Security Printing 293,000 Total Printed Products $ 12,650,000 Nine months ended September 30, 2021 Packaging Printing and Fabrication $ 10,428,000 Commercial and Security Printing 224,000 Total Printed Products $ 10,652,000 Direct Marketing Three months ended September 30, 2022 Direct Marketing Internet Sales $ 4,937,000 Total Direct Marketing $ 4,937,000 Three months ended September 30, 2021 Direct Marketing Internet Sales $ 966,000 Total Direct Marketing $ 966,000 Nine months ended September 30, 2022 Direct Marketing Internet Sales $ 17,939,000 Total Direct Marketing $ 17,939,000 Nine months ended September 30, 2021 Direct Marketing Internet Sales $ 2,382,000 Total Direct Marketing $ 2,382,000 Rental Income Three months ended September 30, 2022 Rental income $ 1,485,000 Total Rental Income $ 1,485,000 Three months ended September 30, 2021 Rental income $ 184,000 Total Rental Income $ 184,000 Nine months ended September 30, 2022 Rental income $ 4,656,000 Total Rental Income $ 4,656,000 Nine months ended September 30, 2021 Rental income $ 184,000 Total Rental Income $ 184,000 Management Fee Income Three months ended September 30, 2022 Management fee income $ 38,000 Total Rental Income $ 38,000 Three months ended September 30, 2021 Management fee income $ - Total Rental Income $ - Nine months ended September 30, 2022 Management fee income $ 38,000 Total Management fee income $ 38,000 Nine months ended September 30, 2021 Management fee income $ - Total Management fee income $ - Net Investment Income Three months ended September 30, 2022 Net Investment Income $ 370,000 Total Investment Income $ 370,000 Three months ended September 30, 2021 Net Investment Income $ - Total Rental Income $ - Nine months ended September 30, 2022 Net investment income $ 644,000 Total Management fee income $ 644,000 Nine months ended September 30, 2021 Net Investment Income $ - Total Management fee income $ -

Basis of Presentation and Sig_3

Basis of Presentation and Significant Accounting Policies (Details Narrative) - USD ($)				3 Months Ended		9 Months Ended
	Dec. 23, 2021	Sep. 13, 2021	Sep. 09, 2021	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Jul. 31, 2020
Product Information [Line Items]
Common stock par value				$ 0.02		$ 0.02		$ 0.02
Inventory adjustments				$ 434,000		$ 434,000		$ 388,000
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer One [Member]
Product Information [Line Items]
Concentration Risk, Percentage						13%	31%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Vendor One [Member]
Product Information [Line Items]
Concentration Risk, Percentage						43%	76%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Vendor Two [Member]
Product Information [Line Items]
Concentration Risk, Percentage						21%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer One [Member]
Product Information [Line Items]
Concentration Risk, Percentage						35%	57%
Warrant [Member]
Product Information [Line Items]
Anti dilutive securities excluded from computation of EPS				0	29,314	11,597	13,596
Share-Based Payment Arrangement, Option [Member]
Product Information [Line Items]
Anti dilutive securities excluded from computation of EPS				0	29,314	11,597	13,596
Sharing Service Global Corp[Member]
Product Information [Line Items]
Equity method investment description of principal activities	On December 23, 2021, DSS purchased 50,000,000 shares at $0.06 per share of Sharing Services Global Corporation (“SHRG”) via a private placement. With this purchase, DSS increased its ownership of voting shares from approximately 47% of SHRG to approximately 58%
Equity method investment ownership percentage	58%								20%
American Pacific Bancorp [Member]
Product Information [Line Items]
Investment amount			$ 40,000,000
Common stock par value			$ 0.01
Business acquisition, share price			$ 6
Sharing Services Global Corp [Member]
Product Information [Line Items]
Stock repurchased during period, shares	50,000,000
Share price	$ 0.06
Stock Purchase Agreement [Member] | American Pacific Bancorp [Member]
Product Information [Line Items]
Investment amount			$ 40,000,200
Number of shares issued on investment			6,666,700
Business acquisition, share price			$ 6
Stock Purchase Agreement [Member] | American Pacific Bancorp [Member] | Common Class A [Member]
Product Information [Line Items]
Common stock par value			$ 0.01
Stock Purchase Agreement [Member] | Liquid Asset Limited Management Limited [Member]
Product Information [Line Items]
Business acquisition, description		Under the terms of this agreement, 4000 shares or 40% of the Company’s subsidiary Liquid Asset Limited Management Limited (“LVAM”), a Hong Kong company was transferred to HR1 whereas at the conclusion of the transaction DFMI would own 60% of LVAM and HR1 would own 40%. LVAM executes within reliable platforms and broad market access and uses proprietary systems and algorithms to trade liquid exchange-traded funds (ETFs), stocks, futures or crypto. Aimed at providing consistent returns while offering the unique ability to liquidate the portfolio within 5 to 10 minutes under normal market conditions, LVAM provides an array of advanced tools and products enabling customers to explore multiple opportunities, strengthen and diversify their portfolios, and meet their individual investing goals

Revenue (Details Narrative)

Revenue (Details Narrative) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
Reserve for doubtful accounts	$ 42,000	$ 20,000

Notes Receivable (Details Narra

Notes Receivable (Details Narrative) - USD ($)

Aug. 29, 2022

Jul. 26, 2022

Dec. 28, 2021

Oct. 25, 2021

Oct. 07, 2021

Sep. 23, 2021

Aug. 30, 2021

May 14, 2021

May 13, 2021

Feb. 21, 2021

Oct. 15, 2020

Jun. 05, 2020

Jun. 13, 2019

Sep. 30, 2022

May 09, 2022

Mar. 02, 2022

Jan. 24, 2022

Dec. 31, 2021

Jun. 18, 2021

Feb. 08, 2021

Short-Term Debt [Line Items]

Debt interest rate

4.25%

Debt instrument, face amount

$ 6,155,000

Maximum [Member]

Short-Term Debt [Line Items]

Debt instrument, face amount

$ 5,105,000

Note Seven [Member]

Short-Term Debt [Line Items]

Debt interest rate

8%

Maturity date

Oct. 25, 2022

Notes receivable

$ 937,000

$ 784,000

Line of credit facility, maximum borrowing capacity

$ 3,000,000

Debt instrument description

This note contains an optional conversion feature allowing APB to convert the outstanding principal to a 10% membership interest

Note Seven [Member] | Maximum [Member]

Short-Term Debt [Line Items]

Debt instrument, face amount

$ 1,000,000

Note Eight [Member]

Short-Term Debt [Line Items]

Debt interest rate

12.50%

15%

15%

Maturity date

May 15, 2023

May 14, 2021

May 15, 2020

Notes receivable

256,000

260,000

Debt instrument, face amount

$ 250,000

$ 250,000

$ 250,000

Note Nine [Member]

Short-Term Debt [Line Items]

Maturity date

Dec. 31, 2021

Debt instrument, face amount

$ 52,000

Notes payable

61,000

52,000

Note Ten [Member]

Short-Term Debt [Line Items]

Debt interest rate

12%

Maturity date

Dec. 28, 2022

Debt instrument, face amount

$ 700,000

Notes payable

759,000

700,000

Note Eleven [Member]

Short-Term Debt [Line Items]

Debt interest rate

6%

Debt instrument, face amount

$ 100,000

Notes payable

104,000

Note Twelve [Member]

Short-Term Debt [Line Items]

Debt interest rate

8%

Notes receivable

446,000

Debt instrument, face amount

$ 893,000

Notes payable

887,000

Note Thirteen [Member]

Short-Term Debt [Line Items]

Debt interest rate

10%

Debt instrument, face amount

$ 210,000

Notes payable

218,000

Note Fourteen [Member]

Short-Term Debt [Line Items]

Debt interest rate

8%

Maturity date

Aug. 29, 2025

Outstanding common stock percentage

24.90%

Debt instrument, face amount

$ 100,000

Notes payable

101,000

Note Fifteen [Member]

Short-Term Debt [Line Items]

Debt interest rate

8%

Maturity date

Jul. 26, 2024

Debt instrument, face amount

$ 1,000,000

Notes payable

917,000

Convertible Promissory Note [Member] | American Premium Water Corporation [Member]

Short-Term Debt [Line Items]

Maturity date

Oct. 15, 2022

Convertible Promissory Note [Member] | Note One [Member]

Short-Term Debt [Line Items]

Outstanding principal and interest

$ 200,000

0

39,000

Debt interest rate

12%

Conversion of debt to equity

$ 39,000

Convertible Promissory Note [Member] | Note Two [Member]

Short-Term Debt [Line Items]

Outstanding principal and interest

0

829,000

$ 800,000

Debt interest rate

4%

Convertible Promissory Note [Member] | Note Three [Member]

Short-Term Debt [Line Items]

Outstanding principal and interest

$ 206,000

206,000

197,000

Debt interest rate

6.50%

Maturity date

Feb. 19, 2024

Convertible Promissory Note [Member] | Note Three [Member] | Bio Medical Inc [Member]

Short-Term Debt [Line Items]

Outstanding principal and interest

16,000

190,000

Convertible Promissory Note [Member] | Note Four [Member]

Short-Term Debt [Line Items]

Debt interest rate

6.65%

Maturity date

May 13, 2023

Outstanding common stock percentage

24.90%

Notes receivable

$ 3,000,000

309,000

0

Convertible Promissory Note [Member] | Note Five [Member]

Short-Term Debt [Line Items]

Outstanding principal and interest

$ 5,000,000

5,333,000

5,081,000

Debt interest rate

6.50%

Maturity date

May 14, 2023

Convertible Promissory Note [Member] | Note Six [Member]

Short-Term Debt [Line Items]

Outstanding principal and interest

$ 3,645,000

Debt interest rate

4.15%

5.60%

Maturity date

Sep. 22, 2022

Debt instrument, face amount

$ 3,500,000

Notes payable

$ 3,650,000

$ 3,540,000

Schedule of Cash and Marketable

Schedule of Cash and Marketable Securities by Significant Investment Category (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Cash and Cash Equivalents [Line Items]
Adjusted Cost	$ 59,684,000	$ 73,929,000
Unrealized Gain/(Loss)	(7,386,000)	1,544,000
Fair Value	52,298,000	75,473,000
Cash and Cash Equivalents	22,845,000	56,595,000
Marketable Securities	28,083,000	14,537,000
Investments	1,370,000	4,341,000
Fair Value, Inputs, Level 2 [Member] | Convertible Securities [Member]
Cash and Cash Equivalents [Line Items]
Adjusted Cost	1,023,000	1,023,000
Unrealized Gain/(Loss)	(725,000)
Fair Value	298,000	1,023,000
Cash and Cash Equivalents
Marketable Securities
Investments	298,000	1,023,000
Fair Value, Inputs, Level 2 [Member] | Investment In Unconsolidated Subsidiaries [Member]
Cash and Cash Equivalents [Line Items]
Marketable Securities
Investments
Fair Value, Inputs, Level 2 [Member] | Warrant [Member]
Cash and Cash Equivalents [Line Items]
Adjusted Cost	3,318,000	3,318,000
Unrealized Gain/(Loss)	(2,246,000)
Fair Value	1,072,000	3,318,000
Cash and Cash Equivalents
Marketable Securities
Investments	1,072,000	3,318,000
Cash [Member]
Cash and Cash Equivalents [Line Items]
Adjusted Cost	21,151,000	50,286,000
Unrealized Gain/(Loss)
Fair Value	21,151,000	50,286,000
Cash and Cash Equivalents	21,151,000	50,286,000
Marketable Securities
Investments
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]
Cash and Cash Equivalents [Line Items]
Adjusted Cost	1,694,000	6,309,000
Unrealized Gain/(Loss)
Fair Value	1,694,000	6,309,000
Cash and Cash Equivalents	1,694,000	6,309,000
Marketable Securities
Investments
Marketable Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Cash and Cash Equivalents [Line Items]
Adjusted Cost	32,498,000	12,993,000
Unrealized Gain/(Loss)	(4,415,000)	1,544,000
Fair Value	28,083,000	14,537,000
Cash and Cash Equivalents
Marketable Securities	28,083,000	14,537,000
Investments
Investment In Unconsolidated Subsidiaries [Member] | Fair Value, Inputs, Level 1 [Member]
Cash and Cash Equivalents [Line Items]
Adjusted Cost
Unrealized Gain/(Loss)
Fair Value
Cash and Cash Equivalents

Acquisitions (Details Narrative

Acquisitions (Details Narrative) - USD ($)		9 Months Ended
	Jan. 24, 2022	Sep. 30, 2022	Dec. 31, 2021	Dec. 23, 2021	Jul. 31, 2020
Business Acquisition [Line Items]
Total current assets		$ 55,668,000	$ 80,305,000
Total assets		264,880,000	282,707,000
Total current liabilities		23,570,000	27,811,000
Sharing Service Global Corp[Member]
Business Acquisition [Line Items]
Total current assets			28,494,000
Total assets			45,660,000
Total current liabilities			10,418,000
Total liabilities			$ 22,463,000
Net income loss		1,632,000
Net income (loss) attribute to non-controlling interest		$ 702,000
Sharing Service Global Corp[Member] | Warrant [Member]
Business Acquisition [Line Items]
Warrants received	50,000,000
Warrants exercise price	$ 0.0001
Sharing Service Global Corp[Member]
Business Acquisition [Line Items]
Ownership percent				58%	20%
Sharing Service Global Corp[Member] | Warrant [Member]
Business Acquisition [Line Items]
Ownership percent	65%

Investments (Details Narrative)

Investments (Details Narrative) - USD ($)										3 Months Ended		9 Months Ended		12 Months Ended
	Jul. 22, 2021	May 13, 2021	Apr. 02, 2021	Mar. 18, 2021	Mar. 15, 2021	Dec. 30, 2020	Dec. 19, 2020	Sep. 10, 2020	Oct. 10, 2019	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Mar. 31, 2022	Jun. 18, 2021
Unrealized gain loss on investments												$ (7,386,000)		$ 1,544,000
Debt interest rate																4.25%
Investments										$ 1,370,000		1,370,000		4,341,000
Gain (loss) on investments										(14,302,000)	$ (2,996,000)	(10,479,000)	$ (10,894,000)
New shares Issued												17,405,000	121,781,000
Investments equity method										1,326,000		1,326,000		1,080,000
Loss before tax										(24,801,000)	(8,299,000)	(39,161,000)	(25,777,000)
Vivacitas Agreement [Member]
Share-based compensation arrangement by share-based payment award, options, exercises in period	1,000,000
Stock issued during period, value, stock options exercised	$ 1,000,000
Shares issued	120,000
Investment cost										4,100,000		4,100,000		4,035,000
Common Stock [Member]
New shares Issued												$ 858,000	$ 1,347,000
Number of shares of common stock												42,924,000	67,340,000
BMI Capital International LLC [Member]
New shares Issued								$ 100,000
Investments equity method										10,000		$ 10,000
Oncology PTELtd [Member]
Options to purchase additional shares				250,000
Consideration transferred				$ 2,480,000
Sentinel Brokers Company Inc [Member]
Investments		$ 750,000									$ 1,050,000		$ 1,050,000
Outstanding membership interest		50.10%
Consideration transferred		$ 300,000
Outstanding membership interest		25%
Additional membership interest		50.10%
Net income loss												143,000
Stemtech Corporation [Member] | Securities Purchase Agreement [Member]
Debt interest rate											10%		10%
Investments											$ 1,400,000		$ 1,400,000
Consideration transferred													$ 1,400,000
Shares issued													154,173
Convertible promissory note											$ 1,400,000		$ 1,400,000
Origination fee													$ 500,000
Loss before tax										$ 8,600,000		$ 3,700,000
Onwership Increment [Member] | BMI Capital International LLC [Member]
Ownership percent								24.90%
BioMed Technologies Asia Pacific Holdings Limited [Member]
Ownership percent							4.99%
New shares Issued							$ 632,000
Number of shares of common stock							525
Common Shares [Member] | Vivacitas Agreement [Member]
Ownership percent										16%		16%
Purchase Agreement [Member] | Sentinel Brokers Company Inc [Member]
Ownership percent		24.90%
Investment Equity [Member] | Sentinel Brokers Company Inc [Member]
Ownership percent										24.90%		24.90%
Membership Unit Purchase Agreement [Member] | Moji Life L L C [Member]
Ownership percent											30.75%		30.75%
Convertible promissory note											$ 1,537,000		$ 1,537,000
Minimum [Member]
Debt interest rate																4.25%
Minimum [Member] | Onwership Increment [Member] | BMI Capital International LLC [Member]
Ownership percent								20%
Alset International Limited [Member]
Owners shares										127,179,311		127,179,311
Outstanding share percentage												4%
Marketable securities										$ 3,370,000		$ 3,370,000		4,909,000
Unrealized gain loss on investments												1,539,000	$ 967,000
Century TBD Holdings, LLC [Member]
Convertible debt									$ 500,000
Debt interest rate									6%
Maturity date									Oct. 09, 2021
Debt instrument, periodic payment														$ 537,000
Century TBD Holdings, LLC [Member] | Maximum [Member]
Convertible debt									$ 500,000
Convertible, threshold percentage									19.80%
West Park Capital Inc [Member]
Convertible, threshold percentage						7.50%
Investments															$ 500,000
Gain (loss) on investments												$ 37,000
DSS Securities, Inc. [Member]
New shares Issued								$ 100,000
Outstanding membership interest								10%
DSS Securities, Inc. [Member] | Onwership Increment [Member]
Ownership percent								14.90%
Vivacitas Oncology Inc [Member]
Number of shares of common stock					500,000
Options to purchase additional shares					1,500,000
Issued price per share					$ 1
Additional price per share					$ 1
Consideration transferred			$ 120,000
Sale of stock, description			the Company entered into an additional stock purchase agreement with Vivacitas (“Vivacitas Agreement #2”), whereas Vivacities wished to employ the service of the Chief Business Officer of Impact Biomedical, and in return for the services of this individual, Vivacitas shall issue to the Company, the aggregate purchase price for the Class A Common Shares of Vivacitas at the value of $1.00 per share shall be $120,000 to be paid in twelve (12) equal monthly installments for the period between April 1, 2021 and March 31, 2022
Vivacitas Oncology Inc [Member] | Common Stock [Member]
Options to purchase additional shares					500,000
Oncology PTELtd [Member]
Owners shares				2,480,000

Short-Term and Long-Term Debt (

Short-Term and Long-Term Debt (Details Narrative)

1 Months Ended

3 Months Ended

9 Months Ended

Aug. 09, 2022 USD ($)

May 17, 2022 USD ($) shares

Mar. 17, 2022 USD ($)

Nov. 02, 2021 USD ($)

Oct. 13, 2021 USD ($)

Jun. 18, 2021 USD ($)

Oct. 31, 2017 USD ($) $ / shares shares

Mar. 31, 2022 USD ($)

Sep. 30, 2022 USD ($)

Sep. 30, 2021 USD ($)

Sep. 30, 2022 USD ($)

Sep. 30, 2021 USD ($)

Dec. 31, 2021 USD ($)

Dec. 31, 2021 a

Dec. 31, 2021 ft²

Nov. 30, 2021 USD ($)

May 20, 2021 USD ($)

Mar. 16, 2021 USD ($)

Mar. 02, 2020 USD ($) $ / shares

Dec. 31, 2019 USD ($)

Short-Term Debt [Line Items]

Debt instrument, face amount

$ 6,155,000

Debt interest rate

4.25%

(Gain) loss on investments

$ (14,302,000)

$ (2,996,000)

$ (10,479,000)

$ (10,894,000)

Long term debt

$ 79,000

Debt Instrument, Term

25 years

5 years

Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid

$ 2,829,000

Area of Land

13.62

40,000

Deferred financing costs

4,821,000

Current portion of long-term debt

216,000

6,680,000

6,680,000

$ 3,916,000

Maximum [Member]

Short-Term Debt [Line Items]

Debt instrument, face amount

$ 5,105,000

Minimum [Member]

Short-Term Debt [Line Items]

Debt interest rate

4.25%

American Medical REIT Inc. [Member]

Short-Term Debt [Line Items]

Debt instrument, face amount

111,000

AMRE Shelton LLC [Member]

Short-Term Debt [Line Items]

Long term debt

$ 4,605,000

Debt Instrument, Description

AMRE Shelton, LLC., (“AMRE Shelton”) a subsidiary of AMRE, entered into a loan agreement (“Shelton Agreement”) with Patriot Bank, N.A. (“Patriot Bank”) in an amount up to $6,155,000,with the amount financed approximating $5,105,000.

Paycheck Protection Program [Member]

Short-Term Debt [Line Items]

Debt instrument, face amount

$ 110,000

Debt interest rate

1%

BMIC Loan [Member]

Short-Term Debt [Line Items]

Debt instrument, face amount

$ 3,000,000

3,068,000

3,068,000

3,000,000

Debt maturity date

Oct. 12, 2022

Wilson Loan [Member]

Short-Term Debt [Line Items]

Debt instrument, face amount

$ 3,000,000

3,000,000

3,000,000

LifeCare Agreement [Member]

Short-Term Debt [Line Items]

Current portion of long-term debt

40,133,000

40,133,000

Alset Note [Member]

Short-Term Debt [Line Items]

Debt instrument, face amount

8,805,000

8,805,000

$ 8,350,000

Debt interest rate

8%

Pinnacle Loan [Member]

Short-Term Debt [Line Items]

Debt instrument, face amount

$ 2,990,000

104,000

104,000

Debt interest rate

4.28%

Long term debt

2,904,000

2,904,000

Debt maturity date

Mar. 07, 2024

American Medical REIT Inc. [Member]

Short-Term Debt [Line Items]

Debt instrument, face amount

$ 8,350,000

Unpaid interest

367,400

Premier Packaging Bank Of America NA [Member]

Short-Term Debt [Line Items]

Debt instrument, face amount

$ 3,521,000

$ 3,521,000

3,339,000

Debt interest rate

4.63%

4.63%

Debt financing amount

$ 3,710,000

(Gain) loss on investments

$ 468,000

Long term debt

$ 3,053,000

3,053,000

Pinnacle Bank [Member]

Short-Term Debt [Line Items]

Debt instrument, face amount

$ 40,300,000

39,448,000

Debt maturity date

Nov. 02, 2024

Deferred Costs

$ 1,002,000

Pinnacle Bank [Member] | LifeCare Agreement [Member]

Short-Term Debt [Line Items]

Current portion of long-term debt

$ 352,000

$ 352,000

Alset International Limited [Member]

Short-Term Debt [Line Items]

Debt instrument, face amount

$ 8,350,000

Shares issued for convertible debt | shares

21,366,177

Unpaid interest

$ 367,000

HWH International Inc [Member]

Short-Term Debt [Line Items]

Debt instrument, face amount

$ 50,000

Conversion of stock | shares

333,333

Warrants to purchase | shares

333,333

Issued price per share | $ / shares

$ 0.15

Cancelleation of warrants and notes

$ 78,635.62

Sharing Service Global Corp[Member]

Short-Term Debt [Line Items]

Debt instrument, face amount

$ 100,000

Unsecured Promissory Note [Member] | American Medical REIT Inc. [Member]

Short-Term Debt [Line Items]

Debt instrument, face amount

$ 200,000

Debt interest rate

8%

Exercise price of warrants | $ / shares

$ 5

Proceeds from warrant exercises

$ 200,000

Schedule of Future Minimum Leas

Schedule of Future Minimum Lease Payments (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Lease Liability
2022	$ 284,000
2023	1,132,000
2024	908,000
2025	877,000
2026	890,000
2027	904,000
After	5,768,000
Total lease payments	10,763,000
Less: Imputed Interest	(1,953,000)
Present value of remaining lease payments	8,810,000
Current	819,000	$ 393,000
Noncurrent	$ 7,991,000	$ 120,000
Weighted-average remaining lease term (years)	14 years 10 months 24 days
Weighted-average discount rate	4.30%

Lease Liability (Details Narrat

Lease Liability (Details Narrative)	3 Months Ended
	Mar. 31, 2022 USD ($)
Minimum [Member]
Operating lease payment	$ 61,000
Maximum [Member]
Operating lease payment	$ 78,000

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)			1 Months Ended	9 Months Ended
	Mar. 19, 2022	Apr. 30, 2019	Apr. 30, 2019	Dec. 31, 2019	Feb. 15, 2021	Apr. 11, 2019
Defined Benefit Plan Disclosure [Line Items]
Royalty percentage	5.50%
Development cost	$ 1,250,000
Maiden Biosciences Inc [Member]
Defined Benefit Plan Disclosure [Line Items]
Executory notes					$ 1,000,000
Outstanding principal and interest					$ 4,329,000
Jeffrey Ronaldi [Member]
Defined Benefit Plan Disclosure [Line Items]
Wages recover				$ 144,658
Salaries un-paid						$ 769
Alleged paid in time off		$ 15,385	$ 15,385
Alleged unpaid		3,077	3,077
Penalties accured		26,077	26,077
Unspecified expense reimbursement			91,000
Jeffrey Ronaldi [Member] | Deferred Bonus [Member]
Defined Benefit Plan Disclosure [Line Items]
Cash bonus		300,000	300,000
Performance bonus			450,000
Jeffrey Ronaldi [Member] | Deferred Profit Sharing [Member]
Defined Benefit Plan Disclosure [Line Items]
Cash bonus		$ 100,000	$ 100,000
Jeffrey Ronaldi [Member] | 2017 Employment Agreement [Member]
Defined Benefit Plan Disclosure [Line Items]
Loss contingency, allegations		In April 2019 DSS commenced an action in New York State Supreme Court, Monroe County, Index No. E2019003542, against Jeffrey Ronaldi, our former Chief Executive Officer. The New York action sought a declaratory judgment that, contrary to informal claims made by him, Mr. Ronaldi’s employment agreement with us expired by its terms and that he is not entitled to any cash bonuses or other unpaid amounts. The lawsuit also sought an injunction against Mr. Ronaldi from interfering with any of DSS’ IP litigation. Mr. Ronaldi subsequently commenced an action against DSS in the Superior Court of California, County of San Diego, on November 8, 2019, under case number 37-2019-00059664-CU-CO-CTL, in which he alleged that DSS terminated his employment in April 2019 in order to avoid paying him certain employment-related amounts. DSS was successful in dismissing the California case and consolidating it with the action pending in Monroe County, New York. Mr. Ronaldi asserted counterclaims in the Monroe County, New York action similar to those he originally brought in California. Mr. Ronaldi claimed that his termination violated an alleged employment agreement or implied-in-fact employment agreement and that he should have remained employed through 2019. Mr. Ronaldi seeks to recover: (i) $144,658 in wages from April 11, 2019 through December 31, 2019; (ii) $769 in alleged unpaid based salary for time worked before April 11, 2019; (iii) $15,385 in alleged paid time off compensation; (iv) $3,077 in alleged unpaid sick time compensation; (v) $26,077 in waiting-time penalties; (vi) $91,000 in unspecified expense reimbursement; (vii) $300,000 in alleged cash bonuses ($100,000 per year) based on DSS’s performance in 2017, 2018 and 2019; and (viii) a $450,000 performance bonus based on the result of certain alleged net proceeds from patent infringement litigation. He further claimed an interest in any recovery in DSS Technology Management v. Apple, Inc., Case No. 4:14-cf05330-HSG

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - USD ($)						1 Months Ended	9 Months Ended
	May 25, 2022	May 17, 2022	May 05, 2022	Mar. 10, 2022	Feb. 28, 2022	Feb. 28, 2022	Sep. 30, 2022	Sep. 30, 2021	Jun. 18, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]
Value of shares consideration							$ 17,405,000	$ 121,781,000
Principal amount									$ 6,155,000
Number of shares issued for acquisition		17,570,948
Stock Based Compensation Expenses [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Share-Based Payment Arrangement, Expense							$ 4,000
True Partners Capital Holdings Limited [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued for acquisition		62,122,908
Alset International Limited [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares issued for convertible debt		21,366,177
Principal amount		$ 8,350,000
Unpaid interest		$ 367,000
Heng Fai Ambrose Chan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares of common stock	15,389,995			894,084
Value of shares consideration	$ 5,847,000			$ 340,000
Frank Heuszel [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares of common stock			63,205
Value of shares consideration			$ 29,000
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares of common stock							42,924,000	67,340,000
Value of shares consideration							$ 858,000	$ 1,347,000
Employee stock purchase plans					3,986,877
Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Principal amount									$ 5,105,000
Stock Purchase Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares of common stock					44,619,423
Issued price per share					$ 0.3810	$ 0.3810
Value of shares consideration					$ 17,000,000	$ 17,000,000
Stock Purchase Agreement [Member] | Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares of common stock					44,619,423
AEI Subscription Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Payments for (Proceeds from) previous acquisition						$ 1,519,000

Schedule of Supplemental Cash F

Schedule of Supplemental Cash Flow Information (Details) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Supplemental Cash Flow Elements [Abstract]
Cash paid for interest	$ 1,907,000	$ 139,000
Non-cash investing and financing activities:
Termination of right of use lease asset		(744,000)
Termination of right of use lease liability		744,000
Shares received for loan origination fee		(3,000,000)
Shares received for prepaid loan interest		(2,440,000)
Notes receivable converted to equity investments	1,940,000
Shares issued for the acquisition of marketable securities	7,169,000
Shares issued for the acquisition of notes receivable	8,717,000
Right of use asset addition	9,895,000
Shares issued in lieu of bonus cash	$ 6,216,000

Schedule of Operations by Repor

Schedule of Operations by Reportable Segment (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Segment Reporting Information [Line Items]
Revenue	$ 11,862,000	$ 4,566,000	$ 35,927,000	$ 13,218,000
Depreciation and amortization	2,927,000	739,000	9,351,000	2,075,000
Interest expense	606,000	31,000	2,105,000	157,000
Interest income	319,000	1,593,000	613,000	3,130,000
Net income (loss) from continuing operations	(24,801,000)	(6,675,000)	(39,161,000)	(21,462,000)
Capital expenditures	373,000	1,640,000	1,349,000	9,381,000
Identifiable assets	264,880,000	219,076,000	264,880,000	219,076,000
Stock based compensation		13,000	4,000	42,000
Income tax benefit		1,624,000		4,315,000
Operating Segments [Member] | Product Packaging [Member]
Segment Reporting Information [Line Items]
Revenue	4,707,000	3,416,000	11,876,000	10,652,000
Depreciation and amortization	168,000	152,000	525,000	459,000
Interest expense	42,000	11,000	100,000	49,000
Interest income
Net income (loss) from continuing operations	(1,077,000)	358,000	(755,000)	641,000
Capital expenditures	300,000	1,399,000	1,242,000	2,621,000
Identifiable assets	24,035,000	24,752,000	24,035,000	24,752,000
Stock based compensation		1,000	1,000	2,000
Income tax benefit
Operating Segments [Member] | Commercial Banking [Member]
Segment Reporting Information [Line Items]
Revenue	370,000		644,000
Depreciation and amortization
Interest expense
Interest income
Net income (loss) from continuing operations	221,000	64,000	638,000	64,000
Capital expenditures
Identifiable assets	48,121,000	60,388,000	48,121,000	60,388,000
Stock based compensation
Income tax benefit
Operating Segments [Member] | Direct Marketing Online Sales [Member]
Segment Reporting Information [Line Items]
Revenue	4,956,000	966,000	18,000,000	2,382,000
Depreciation and amortization	41,000	100,000	248,000	419,000
Interest expense	193,000		193,000	2,000
Interest income	3,000
Net income (loss) from continuing operations	(15,379,000)	(1,304,000)	(19,102,000)	(9,088,000)
Capital expenditures	73,000		88,000	6,000
Identifiable assets	39,979,000	43,695,000	39,979,000	43,695,000
Stock based compensation
Income tax benefit
Operating Segments [Member] | Biotechnology [Member]
Segment Reporting Information [Line Items]
Revenue			94,000
Depreciation and amortization	278,000	278,000	835,000	835,000
Interest expense				1,000
Interest income	94,000
Net income (loss) from continuing operations	(909,000)	(647,000)	(2,198,000)	(1,955,000)
Capital expenditures
Identifiable assets	57,225,000	55,848,000	57,225,000	55,848,000
Stock based compensation
Income tax benefit
Operating Segments [Member] | Securities [Member]
Segment Reporting Information [Line Items]
Revenue	1,646,000	184,000	4,817,000	184,000
Depreciation and amortization	2,423,000	135,000	7,637,000	134,000
Interest expense	371,000	37,000	1,812,000	87,000
Interest income	79,000
Net income (loss) from continuing operations	(3,182,000)	(835,000)	(8,334,000)	(1,066,000)
Capital expenditures		186,000	15,000	6,750,000
Identifiable assets	81,766,000	11,376,000	81,766,000	11,376,000
Stock based compensation
Income tax benefit
Operating Segments [Member] | Corporate Segment [Member]
Segment Reporting Information [Line Items]
Revenue	183,000		496,000
Depreciation and amortization	17,000	74,000	106,000	228,000
Interest expense		(17,000)		18,000
Interest income	143,000
Net income (loss) from continuing operations	(4,475,000)	(4,311,000)	(9,410,000)	(10,058,000)
Capital expenditures		55,000	4,000	4,000
Identifiable assets	$ 13,754,000	23,017,000	13,754,000	23,017,000
Stock based compensation		12,000	$ 3,000	40,000
Income tax benefit		$ 1,624,000		$ 4,315,000

Schedule of Disaggregation of R

Schedule of Disaggregation of Revenue (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Segment Reporting Information [Line Items]
Total Printed Products	$ 5,032,000	$ 3,416,000	$ 12,650,000	$ 10,652,000
Total Direct Marketing	4,937,000	966,000	17,939,000	2,382,000
Total Rental Income	1,485,000	184,000	4,656,000	184,000
Total management Fee Income	38,000		38,000
Total Investment fee income	370,000		644,000
Packaging Printing and Fabrication [Member]
Segment Reporting Information [Line Items]
Total Printed Products	4,888,000	3,373,000	12,357,000	10,428,000
Commercial and Security Printing [Member]
Segment Reporting Information [Line Items]
Total Printed Products	144,000	43,000	293,000	224,000
Direct Marketing Internet Sales [Member]
Segment Reporting Information [Line Items]
Total Direct Marketing	4,937,000	966,000	17,939,000	2,382,000
Rental Income [Member]
Segment Reporting Information [Line Items]
Total Rental Income	1,485,000	184,000	4,656,000	184,000
Management Fee Income [Member]
Segment Reporting Information [Line Items]
Total management Fee Income	38,000		38,000
Net Investment Income [Member]
Segment Reporting Information [Line Items]
Total Investment fee income	$ 370,000		$ 644,000

Segment Information (Details Na

Segment Information (Details Narrative)	9 Months Ended
	Sep. 30, 2022 Segments
Segment Reporting [Abstract]
Number of operating segments	5

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)

1 Months Ended

9 Months Ended

12 Months Ended

Aug. 09, 2022

May 17, 2022

Feb. 28, 2022

Nov. 30, 2021

Oct. 13, 2021

Oct. 07, 2021

Sep. 09, 2021

May 13, 2021

Mar. 18, 2021

Sep. 10, 2020

Aug. 28, 2020

Oct. 31, 2017

Mar. 31, 2022

Feb. 28, 2022

Sep. 30, 2022

Sep. 30, 2021

Dec. 31, 2021

Jul. 02, 2022

Jun. 18, 2021

Mar. 02, 2020

Unrealized loss on investment

$ (7,386,000)

$ 1,544,000

Principal amount

$ 6,155,000

Debt interest rate

4.25%

Common stock, par value

$ 0.02

$ 0.02

Issuance of common stock, net of expenses

$ 17,405,000

$ 121,781,000

Number of shares issued for acquisition

17,570,948

Common Stock [Member]

Number of shares of common stock

42,924,000

67,340,000

Issuance of common stock, net of expenses

$ 858,000

$ 1,347,000

Employee stock purchase plans

3,986,877

BMIC Loan [Member]

Principal amount

$ 3,000,000

3,068,000

$ 3,000,000

Debt maturity date

Oct. 12, 2022

Wilson Loan [Member]

Principal amount

$ 3,000,000

3,000,000

Alset Note [Member]

Principal amount

$ 8,350,000

8,805,000

Debt interest rate

8%

Debt maturity, description

December 2023, with interest due quarterly and the principal due at maturity

Stock Purchase Agreement [Member]

Number of shares of common stock

44,619,423

Issued price per share

$ 0.3810

$ 0.3810

Issuance of common stock, net of expenses

$ 17,000,000

$ 17,000,000

AEI Subscription Agreement [Member]

Payments for (Proceeds from) previous acquisition

$ 1,519,000

Note Nine [Member]

Principal amount

$ 52,000

Debt maturity date

Dec. 31, 2021

Notes Payable

61,000

52,000

Americans Pacific Bancorp [Member]

Ownership percent

2%

Oncology PTELtd [Member]

Consideration transferred

$ 2,480,000

Options to purchase additional shares

250,000

American Pacific Bancorp [Member]

Business acquisition equity interest issued

$ 40,000,000

Number of shares of common stock

6,666,700

Common stock, par value

$ 0.01

Business acquisition share price

$ 6

Business acquisition percent

53%

General and administrative expense

$ 36,000

Net income loss

645,000

Noncontrolling interest

$ 306,000

American Pacific Bancorp [Member] | Stock Purchase Agreement [Member]

Business acquisition equity interest issued

$ 40,000,200

Business acquisition share price

$ 6

True Partners Capital Holdings Limited [Member]

Number of shares issued for acquisition

62,122,908

Alset International Limited [Member]

Investment owned balance shares

127,179,311

Warrants percentage

4%

Marketable securities

$ 3,370,000

4,909,000

Unrealized loss on investment

1,539,000

$ 967,000

Principal amount

$ 8,350,000

Shares issued for convertible debt

21,366,177

Unpaid interest

$ 367,000

American Medical REIT Inc. [Member]

Principal amount

8,350,000

Unpaid interest

$ 367,400

American Medical REIT Inc. [Member] | Unsecured Promissory Note [Member]

Principal amount

$ 200,000

Debt interest rate

8%

Exercise price of warrants

$ 5

Proceeds from warrant exercises

$ 200,000

Oncology PTELtd [Member]

Investment owned balance shares

2,480,000

DSS Securities, Inc. [Member]

Acquistion description

On or about August 28, 2020, the Company’s wholly owned subsidiary, DSS Securities, Inc. entered into a corporate venture to form and operate a real estate title agency, under the name of Alset Title Company, Inc, a Texas corporation (“ATC”). DSS Securities, Inc. shall own 70% of this venture with the other two shareholders being attorneys necessary to the state application and permitting process. The Company’s CEO, who is a licensed attorney, has a stated non-compensated 15% ownership interest in the venture. There was minimal activity for the nine months ended September 30, 2022

Issuance of common stock, net of expenses

$ 100,000

Sentinel Brokers LLC [Member]

Aggregate principal

$ 3,000,000

Line of credit facility interest rate

6.65%

Expiration date

May 13, 2023

Outstanding amount

309,000

$ 0

Conversion of stock amount converted

$ 1,364,000

Preferred shares of borrower

13.64

HWH International Inc [Member]

Principal amount

$ 50,000

Issued price per share

$ 0.15

Conversion of stock

333,333

Warrants to purchase

333,333

Cancelleation of warrants and notes

$ 78,635.62

Alset EHome [Member]

Share price

$ 0.34

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Oct. 20, 2022	Jun. 18, 2021
Subsequent Event [Line Items]
Debt face amount		$ 6,155,000
Interest rate		4.25%
Sentinel Brokers LLC [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Debt face amount	$ 1,000,000
Interest rate	8%